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Abstract
Bordetella bronchiseptica colonizes the upper respiratory tract of a wide variety
of mammals and is involved in diseases such as kennel cough in dogs, atrophic
rhinitis in pigs and upper respiratory tract infections of laboratory animals. Studies
were focused on developing a heterologous antigen expression system in B.
bronchiseptica and to evaluate the potential of this organism as a candidate mucosal
vaccine vector. Since the role of Bordetella bronchiseptica and Pasteurella multocida
toxin (PMT) in the disease atrophic rhinitis of pigs was well documented, this
research was focused in the possibility of developing a refined vaccine to control this
disease. A promoter region related to heat shock protein genes was identified using a
green fluorescent protein reporter system. This promoter drove high- level expression
of GFP compared to a tac promoter or B. bronchiseptica fim N gene promoter. A nontoxic protective P. multocida toxin fragment and GFP were expressed in B.
bronchiseptica in a broad-host-range plasmid vector PBBR1MCS2 under the control
of the promoter region identified. Colonization kinetics, plasmid stability, and
immune responses generated following intranasal inoculation of recombinant B.
bronchiseptica were evaluated. While wild type and recombinant B. bronchiseptica
colonized the mouse respiratory tract effectively, the plasmid was completely lost
from the organism after 72 hours post- inoculation. After a single intranasal
inoculation, B. bronchiseptica specific IgM, IgA and IgG responses were detected in
serum and respiratory lavage. However, PMT-specific antibodies were not detected.
Four intranasal inoculations with B. bronchiseptica expressing green fluorescent
protein (GFP) induced a GFP-specific systemic and mucosal immune response, while
iv

similar inoculations with B. bronchiseptica expressing PMT fragment did not induce
a PMT-specific immune response.
This study also evaluated the immune response to a chimeric protein generated
by combining a gene fragment encoding neutralizing epitopes of Mannheimia
haemolytica leukotoxin and a fimbrial protein gene (fim N) from B. bronchiseptica.
Immunization of mice with the recombinant chimeric protein elicited a significantly
stronger anti- leukotoxin antibody response than comparable immunizations with
fusion proteins lacking FIM N. The chimeric protein exhibited more stability.
Leukotoxin is an important virulence factor in shipping fever pneumonia in feedlot
cattle and is a critical protective antigen. This chimeric protein may be a candidate for
inclusion in new generation vaccines against shipping fever pneumonia. The results
of these studies strongly support the potential for developing B. bronchiseptica as a
candidate mucosal vaccine vector and FIM N as a carrier protein for heterologous
antigens.
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Literature Review
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Introduction
Bordetella bronchiseptica is an upper respiratory tract pathogen, which infects a wide
variety of host species including domestic, laboratory and wild animals and may also
opportunistically infect human beings [33, 60]. B. bronchiseptica is involved in diseases
such as kennel cough in dogs, and atrophic rhinitis in swine [60]. This organism is an
adept colonizer of the upper respiratory tract of mammals and colonization is
characterized by attachment to the ciliated epithelium [6, 7, 8, 9]. The attachment is
achieved by the expression of adhesins such as fimbriae, filamentous haemagglutinin and
pertactin [33, 81, 147].
Atrophic rhinitis is an upper respiratory tract disease of pigs characterized by
degeneration and atrophy of nasal turbinate bones in market weight hogs, leading to
visible distortion and shortening of the snout [20, 60, 67, 165, 169]. The infection with B.
bronchiseptica leads to a mild reversible form of atrophic rhinitis, whereas, infection with
Pasteurella multocida leads to a severe progressive form of atrophic rhinitis [1, 113, 165
166]. Toxins produced by B. bronchiseptica and Pasteurella multocida are involved in
this disease condition [36, 37, 48, 49, 50, 91, 92, 93]. Dermonecrotic toxin produced by
virulent strains of B. bronchiseptica can induce impaired osteoblastic differentiation and
atrophic rhinitis in pigs, rabbits and mice [104, 113].
Pasteurella multocida is an important veterinary pathogen involved in diseases such
as atrophic rhinitis in swine, fowl cholera in birds, hemorrhagic septicemia in cattle and
other respiratory diseases in lab animals [20, 21]. Pasteurella multocida toxin (PMT)
produced by capsular type D or type A strains of P. multocida is a major virulence factor
in atrophic rhinitis [40, 148, 149, 184]. This toxin is a potent, intracellular, heat labile,
2

146kD protein that induces bone resorbtion through increased osteoclastic and impaired
osteoblastic activity [66, 91, 92, 93, 98, 115, 116, 146, 151, 166]. It also causes
degeneration and necrosis of liver, pneumonia, spleenic atrophy, orchitis and
proliferation of bladder epithelium in experimental animals [48, 49]. PMT triggers a
number of signal transuduction pathways leading to cytoskeletal rearrangement [182,
195]. The role played by P. multocida and B. bronchiseptica in atrophic rhinitis is well
documented [34, 36, 37]. A mutualistic disease-causing relationship exists between these
two organisms [34, 36, 37]. Colonization with B. bronchiseptica predisposes animals to
infection with P. multocida, which may lead to a severe atrophic rhinitis and financia l
losses in the swine industry [1, 20]. PMT, itself, can also lead to a severe form of atrophic
rhinitis when inoculated into experimental animals [48, 49].
Atrophic rhinitis vaccines initially consisted of different preparations of killed or live
avirulent B. bronchiseptica. After elucidating the role of PMT in atrophic rhinitis, the use
of PMT toxoid or non-toxic recombinant derivatives provided a significant degree of
protection from PMT induced atrophic rhinitis and now most vaccines consist of B.
bronchiseptica bacterin/ live attenuated vaccines and P. multocida bacterin and toxoid
[12, 48, 49, 89, 142, 184].
Considering the synergistic role of B. bronchiseptica and P. multocida in atrophic
rhinitis, further development of combined vaccines seems to be a rational approach to
control this disease. A mucosal immune response to B. bronchiseptica will lead to
immunological elimination of B. bronchiseptica thus preventing colonization with P.
multocida and other respiratory pathogens. Anti-PMT-antibodies will reduce the
incidence of PMT-induced atrophic rhinits.
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The mucosal surfaces are the portals of entry of many pathogens and they constitute
the first lines of defense against pathogens [118, 119]. Attachment properties of B.
bronchiseptica could be effectively utilized to deliver heterologous antigens to the
respiratory tract for the purpose of inducing protective mucosal immune responses
against respiratory pathogens.
The major goal of this study was to explore the possibility of B. bronchiseptica as a
candidate mucosal vaccine vector.
Specific aims of this study were:
1. To identify and isolate a constitutive promoter from B. bronchiseptica
using a green fluorescent protein reporter system.
2.

To clone and express a non-toxic P. multocida toxin fragment under the
control of a suitable promoter.

3.

To study colonization, plasmid stability and antibody response following
intranasal inoculation with B. bronchiseptica expressing the PMT
fragment.

4. To evaluate the efficacy of Fim N protein of B. bronchiseptica as a
carrier protein for heterologous antigens.
The Genus Bordetella
Bordetellae are small, gram negative, aerobic, non-acid fast, non-spore forming
coccobacilli [81, 147, 150]. All species of Bordetella are asaccharolytic [81, 147, 150].
They utilize amino acids and other organic acids as sources of energy [81, 147, 150].
Their optimum temperature for growth is 35-37o C. The members of this genus are B.
pertusiss, B. parapertussis, B. bronchiseptica, B. avium, B. hinzi, B. holmesii,
4

B. trematum and B. petrii [33, 81, 147, 150]. All the members of this genus are catalase
positive. B. pertussis is the most fastidious species within the genus, and does not grow
on simple media [81, 147, 150]. Other Bordetella species are less fastidious except B.
parapertussis and B. holmeseii, which are relatively slow growing [81, 147, 150]. Nitrate
reduction, urease, oxidase and motility tests can be utilized to differentiate species [81,
147, 150]. The members of this genus are closely related, genetically, and their DNAs
have a G+C content of 60.2 -70% [147].
B. pertussis is strictly a human pathogen responsible for whooping cough in
children,and pertussis in adolescents and elderly humans [33, 147, 188]. This is an acute,
highly contagious disease in children characterized by characteristic paroxysmal
coughing. B. parapertussis is also a human adapted pathogen and causes pertussis- like
syndrome in humans [81, 147, 150]. It has also been isolated from cases of chronic nonprogressive pneumonia in sheep [33, 147]. Bordetella avium is responsible for a
condition known as coryza or rhinotracheitis in turkey poults and chickens [81, 147, 150].
This disease condition is highly contagious and predisposes birds to secondary infections
[87]. Bordetella bronchiseptica has been associated with acute tracheobronchitis or
kennel cough in dogs and atrophic rhinitis in swine [6, 7, 8, 9, 60]. This organism can
also cause upper respiratory tract infection of a wide variety of mammals such as mice,
rabbits, guinea pigs, cats, and horses [60].
B. hinzii, has been isolated from the respiratory tract of immunocompromised human
beings, healthy turkeys, and chickens [81, 147, 150]. B. holmesii, has been isolated from
human beings with respiratory tract infection and septicemia [81, 147, 150]. B. trematum
has been isolated from human beings with wound infections and otitis media [33, 81,
5

147, 150]. B. petrii, the new member of this genus, was isolated from an anaerobic
bioreactor [191]; however, there is very little information available on this species.
The population structure of the Bordetella genus has been subjected to extensive
evolutionary studies. The close phylogenetic relationship of Bordetella with Alcaligenes
and other environmental bacteria suggests that the ancestral Bordetellae were free- living
and evolved to infect warm-blooded animals [156]. The 16S ribosomal RNA analysis
placed B. bronchiseptica as the nearest relative to bacterial endosymbionts in protozoa
[156]. Musser et al. obtained an estimate of genetic relatedness of 60 strains of
mammalian Bordetellae from worldwide sources by utilizing multilocus enzyme
electrophoresis of 15 metabolic enzymes [137]. Van der Zee et al. also attempted to
differentiate members of this genus by comparing the electrophoretic mobilities of
metabolic enzymes [190]. Multilocus sequence typing based on sequencing of a portion
of house keeping genes and insertion sequences were also utilized to compare the
evolutionary relationship of members of the genus [61, 156, 190]. These studies
concluded that B. pertussis, B. parapertussis and B. bronchiseptica are subtypes of a
single genomic species. B. avium, B. holmesii, and B. hinzii each form true genomic
species [190]. It was proposed that B. bronchiseptica may be the evolutionary progenitor
and other species may be considered as host adapted lineages of B. bronchiseptica [61,
156, 190]. The sequence comparison of genes encoding fimbrial subunits, adenylate
cyclase toxin, pertactin, pertussis toxin and BvgAS, confirmed the close relationship
between B. bronchiseptica and B. parapertussis and a more distant relationship between
these species and B. pertussis [33, 190]. Also, human and sheep isolates of B.
parapertussis comprise genetically distinct population [33, 190]
6

Gene regulation in Bordetella
Virulence gene expression in Bordetella spp is controlled by a two-component signal
transduction system encoded by the Bordetella virulence gene (bvg) locus [187, 196,
197]. Some of the virulence factors controlled by this system include fimbriae,
filamentous haemagglutinin, pertactin, pertussis toxin, adenylate cyclase toxin and
dermonecrotic toxin. The BvgAS system is a two component signal transduction system
controlled by proteins, BvgS (a sensory transmembrane protein) and a transcriptional
activator BvgA (a cytoplasmic DNA binding protein) [33, 196, 197]. This locus is
activated by temperatures above 37o C, and low sulfate or nicotinic acid concentrations
resulting in expression of virulence factors [33, 196, 197].
A second set of genes is activated when the locus is shut down by low temperature
(less than 30o C) or in the presence of increased sulfate or nicotinic acid concentration.
Genes involved in flagella synthesis and urease expression [121, 131, 198] in B.
bronchiseptica are negatively regulated by the bvg locus. However, in human isolates of
B. parapertussis urease is repressed by bvg locus whereas in sheep isolates of B.
parapertussis it is not under the control of bvg locus [33]. In some strains of
B. bronchiseptica, genes involved in alcaligin biosynthesis are negatively regulated by
the bvg locus [58]. In B. pertussis, five genes (vrg6, vrg18, vrg24, vrg53, vrg73) which
involve a second intermediate regulatory locus, bvgR (a transcriptional repressor) were
discovered [101, 126].
Phenotypic modulation was described in earlier literature as the reversible loss of
virulence-associated phenotypes that happens in response to changes in environmental
conditions [196, 197]. Many of the earlier descriptions of the phases (phase I to phase IV)
7

were based on colony morphotypes. The virulence phase was called X mode (now known
as bvg positive). X mode is seen at 37o C and in the presence of certain chemical ions such
as sodium, potassium, halides, formate, and nitrate [33, 196, 197]. The avirulent phase,
called C mode (now known as bvg negative) was seen at low temperatures and in the
presence of ions such as sulfate and nicotinic acid [33, 196, 197]. Phase variatio n is the
irreversible loss of virulent phenotype due to mutations occurring in the bvg-locus [33,
196, 197]. In B. bronchiseptica, positively regulated traits (Bvg+) were required for
respiratory infection. Whereas, negatively regulated traits (Bvg-) were required for
surviving nutrient limitation [30].
A recent study described another phase called bvg intermediate phase (Bvgi), when B.
bronchiseptica was grown in semi- modulating conditions [31]. This phase was
characterized by the presence of one subset of bvg+ factors with the absence of other
bvg+ factors and the presence of factors, which are exclusively expressed in this phase
[31]. Isolates with Bvgi phenotypes displayed reduced virulence in a rat model of
respiratory tract infection and increased ability to survive nutrient deprivation [31].
Stockbauer et al. described a protein called BipA, and its gene, which was exclusively
expressed, in the Bvg intermediate phase [183]. A second two-component sensory
transduction system called "ris" has been described in B. bronchiseptica. This system had
similarities to the bvg system and was up regulated at 37o C and down regulated at lower
temperatures or in the presence of magnesium ions [90].
Bordetella virulence factors
Colonization of Bordetella in the upper respiratory tract of the host is mediated
through strong attachment to the ciliated epithelium. A number of adhesins such as
8

fimbriae, filamentous haemagglutinin, and pertactin have been recognized. Heavy
colonization with production of toxins like dermonecrotic toxin, adenylate cyclase,
tracheal cytotoxin, pertussis toxin, and endotoxin will lead to inflammatory responses in
the respiratory tract that may produce significant clinical disease [33, 147, 150]. Major
virulence factors produced by members of the genus Bordetella are discussed below.
B. pertussis is known to produce pertussis toxin, which is the important virulence
factor in whooping cough in children [141]. B. bronchiseptica and B. parapertussis also
contain the pertussis toxin gene, but do not express pertussis toxin [2, 73]. This is due to
the differences in sequences in the promoter region, which make the toxin inactive [73].
Replacement of the pertussis toxin promoter region in B. bronchiseptica and B.
parapertussis with tha t of B. pertussis resulted in expression of active toxin [73]
Adenylate cyclase toxin (ACT) is a member of the RTX (repeat in toxin) family of
bacterial toxins [59, 63]. RTX toxins are a family of pore- forming proteins of Gramnegative bacteria, which contain glycine-aspartic acid rich repeats [52]. This toxin has
bifunctional activity as a hemolysin and adenylate cyclase toxin. Adenylate cyclase and
hemolytic activity are separable [157]. ACT can enter eukaryotic cells through pore
formation and become activated by calmodulin, which leads to the production of
unregulated cyclic AMP levels [59, 63, 75, 114, 157]. ACT is a 216 kD secreted protein
and is produced by all members of the Bordetella genus except B. avium [33, 147, 157].
The major differences in amino acid sequence of adenylate cyclase toxin between B.
bronchiseptica and B. pertussis were located on the carboxy terminal repeat region of the
molecule [10]. Harvill et al. studied wild-type and mutants of B. bronchiseptica with
alterations in adenylate cyclase toxin and concluded that phagocytic cells are the primary
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targets of this toxin [71]. ACT is unique among the RTX toxins; in that it has enzymatic
activity as well as the capacity to form an ion-permeable pore in target cell membranes.
The latter causes lysis of erythrocytes, which is a colony, associated phenotype that can
be easily seen on Bordet-Gengou agar containing horse or sheep blood cells [75, 157].
ACT mutants were defective in colonization [71]. The protective nature of ACT
antibodies against infection suggests that this toxin is required for initial colonization [59,
97]. ACT down regulates the phagocytic activity of neutrophils and macrophages and can
induce apoptosis in macrophages [10, 71]. The antigenic and protective properties of
adenylate cyclase toxin of B. bronchiseptica are different from that of B. pertussis [10,
75].
Dermonecrotic toxin (DNT) is a 162 kD, intracellular, dermonecrotic, thermolabile
and mitogenic cytotoxin produced by Bordetella spp. [138, 154, 194]. DNT can impair
osteoblastic differentiation and is an important virulence factor in atrophic rhinitis in
pigs, rabbits and mice [104, 113, 162]. DNT is cytotoxic for Vero cells, embryonic
bovine lung cells and bovine turbinate cells [83, 178]. It induces morphological changes
in cultured fibroblasts, including the assembly of actin, stress fiber formation, focal
adhesion assembly, multinucleation and is a potent mitogen [83, 104, 178]. DNT
deamidates the Gln 63 residue of small G proteins like Rho, Rac and Cdc42 leading to
their constitutive activation and polymerization of actin [83, 95, 178]. DNT shows
structural and functional homology to Cytotoxic Necrotizing Factor I of E. coli and
deamidation activity of both these toxins are mapped to their C- terminus [110].
Tracheal cytotoxin (TCT) is a muramyl peptide released by Bordetellae, [74, 112]
and is responsible for specific epithelial pathology in whooping cough. TCT stimulated
10

production of IL1 and formation of large amounts of nitric oxide result in damage to
ciliated epithelial cells [33, 74, 112]. It has been suggested that TCT may also be
involved loss of ciliary activity and colonization of the organism in the respiratory tract
[9, 29].
Pertactin (PRN) is an outer membrane protein, and a nonfimbrial adhesin that belongs
to the family of autoexporters [22, 42, 109, 111]. Autoexporter/ autotransporters are
proteins, which have the ability to export themselves to the outer membrane, cleave
themselves via protease activity and release fina l product into the medium [70]. Pertactin
was initially identified in B. bronchiseptica as a 68kD protein [132]. It is a 69kDa
protein in B. pertussis and a 70kD protein in B. parapertussis [22, 132]. Pertactin
contains one RGD (arginine-glycine-aspartic acid) motif and several proline rich as well
as leucine rich repeats involved in eukaryotic cell binding [33, 109]. Pertactin is also a
protective antigen that is included in acellular pertussis vaccines. Although pertactin can
function as a nonfimbrial adhesin and can induce a protective antibody response against
Bordetella, its role in pathogenesis is unknown [33]. Recently genetic and phenotypic
heterogeneity has been reported in strains of B. bronchiseptica and B. pertussis [135,
158]. This variation, which occurs in the repeat sequence motifs, is believed to be due to
antigenic drift occurring in immunized populations.
Other Bordetella proteins with predicted autoexport properties include Tracheal
Colonization Factor [47] BrkA [45, 163] and Vag8 [46]. These proteins share amino acid
sequence homology at their C terminus, contain RGD motifs and are detected only in B.
pertussis.
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Filamentous haemagglutinin (FHA) is a high molecular weight, secreted outer
membrane protein reported in B. bronchiseptica, B. pertussis, B. parapertussis [33, 86,
145]. FHA is a major attachment factor and protective antigen in Bordetella [108]. There
are important domains in FHA, including a RGD motif, a carbohydrate-binding site and a
heparin-binding site [68, 153, 159, 160], which are involved in eukaryotic cell binding.
The RGD sequence of FHA binds to the integrin, CR3, of macrophages, which may
promote phagocytosis. Attachment of FHA to ciliated cells is mediated through the
carbohydrate-binding domain [153, 159, 160]. The heparin-binding domains of FHA may
help in low affinity binding of the bacteria to the extracellular matrix of the upper
respiratory tract [68, 122]. FHA is highly immunogenic and antibodies to FHA prevent
attachment of B. pertussis and B. bronchiseptica [86, 96]. FHA is also a good mucosal
immunogen as evidenced by high levels of anti-FHA antibodies in infected individuals
[33, 86, 96, 108, 152]. In one study, FHA enhanced the mucosal immunogenicity of
liposome delivered antigen administered via intranasal route [152]
Cotter et al. suggested that, FHA mediated attachment to tracheal epithelium allowed
Bordetella to overcome constitutive mucociliary mechanisms in the trachea [32]. FHA
appears to be secreted in lower amount in B. bronchiseptica compared to B. pertussis [86,
88, 108]. It was postulated that the different levels of FHA expression in these species
might be due to differences in protein production, differences in cell envelope
composition and structures that affect export from cells or degradation [88].
Fimbriae produced by B. bronchiseptica species are important virulence factors
which help in adherence and colonization of the bacteria to host tissues [99]. Fimbriae are
heteropolymeric filamentous appendages that are involved in attachment of many Gram12

negative bacteria. They are highly immunogenic, antigenically stable proteins that are
included as components of many acellular vaccines [89]. Major fimbrial subunit genes of
B. bronchiseptica are fim2, fim3, fimX, fimA and fimN [13, 17, 94, 133, 134, 172, 199,
200]. The fimbrial proteins of B. bronchiseptica and B. pertussis are serologically crossreactive. Fimbrial biogenesis is a complex process involving a cluster of genes called
fimABCD [85, 99]. These are located in the FHA operon immediately downstream to
fhaB, the structural gene for filamentous haemagglutinin. A mutation in FimB can abolish
the expression of fimbriae [117]. Major fimbrial subunit genes are located elsewhere in
the chromosome [99]. Fim A encodes a major structural subunit that is nonfunctional in
B. pertussis but is expressed in B. bronchiseptica [13]. Fim D, a minor fimbrial subunit
produced by B. pertussis, is a putative adhesin and tip protein [57]. The sequence of fimD
in B. bronchiseptica differs by only one base pair from that in B. pertussis. Mutation in
fimD blocks the expression of major fimbrial subunits suggesting that it may have
chaperone like activity [57]. The propensity for frequent deletion or addition of bases in a
cytosine-rich sequence within the Bordetella fimbrial promoter region is a proposed
mechanism for fimbrial type-switching, a phenomenon which enables Bordetella to
express one type, two types or no fimbriae at a given point of time [200]. This may be
attributed to selective pressure driven by the host's immune response or there may be
differences in host receptors that induce the expression of a particular fimbrial gene.
Receptors for fimbriae contain sulfated sugars like heparin sulfate, which are ubiquitous
in the respiratory tract [55, 56]. Sequences similar to the heparin-binding region of
fibronectin have been evaluated in fim2 and fim3 subunits of B. pertussis [55, 56]. Studies
on expression of B. pertussis fimbriae in E. coli revealed that a recombinant subunit
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protein was immunonologically and antigenically distinct from the native fimbriae and
exhibited limited cross reactivity [192, 193]. Quaternary structure generated by subunit
interaction of the fimbrial protein may be necessary for its incorporation as a protective
immunogen in vaccines. Fimbriae are required for establishment of persistent
colonization of the trachea in mice and may play a role in the development of a humoral
immune response to Bordetella infection [117].
The products of Type III secretion systems are other newly identified factors involved
in B. bronchiseptica virulence [206, 207]. Type III secretion allows Gram- negative
bacteria to translocate molecules into the cytoplasm of eukaryotic cells [202]. These
products interact with a variety of eukaryotic signal transduction pathways to promote
bacterial-host interactions [202]. In B. bronchiseptica the type III secretion products are
specially transcribed under Bvg+ conditions [206]. These products are highly
immunogenic in rabbits and are required for in vitro cytotoxicity [33, 206, 207]. These
products may also be expressed by B. pertussis and sheep isolates of B. parapertussis
[33]. Yuk et al. investigated the functions of the type III secretion system in B.
bronchiseptica by comparing the wild-type bacteria with two strains that were defective
in type III secretion system [206, 207]. The mutants were defective in long-term
colonization of the trachea in immunocompetent mice. Also, mutants induced high titers
of anti-bordetella antibodies compared to wild-type. The authors suggested that type III
secretion products interacted with components of innate and adaptive immune systems of
the host and that these products were required for inducing apoptosis in macrophages in
vitro and increasing the influx of inflammatory cells in vivo. This modulation of immune
response may be achieved through inactivating NF-kB, a transcription factor for
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regulation of genes involved in immune response [206]. Winstanley et al. investigated
and confirmed the presence of a type III secretion system in animal isolates of B.
bronchiseptica [201].
The lipopolysaccharide (LPS) molecules of members of the Bordetella genus differ in
their structure [33]. B. pertussis contains a complex trisaccharide with no O antigen.
Therefore, it is generally referred as lipo-oligosaccharide. B. bronchiseptica has a
trisaccharide plus an O- antigen repeat and B. parapertussis has an altered trisaccharide
plus O-antigen-like repeat [72]. The wlb gene cluster, composed of 12 genes, is required
for biosynthesis and addition of the trisaccharide in B. pertussis and B. bronchiseptica
and O-antigen- like repeat in B. bronchiseptica and B. parapertussis [72]. Harvil et al.
investigated the effect of mutation of wlb locus on colonization of B. bronchiseptica in
the respiratory tracts of mice. They observed that biosynthesis of full length LPS, by
these three Bordetellae are essential for virulence in mice [72]. However, LPS molecules
of these species play different roles in infection [72]. Changes in LPS expression in B.
bronchiseptica is controlled by BvgAS system [189]. When resistance profiles of B.
bronchiseptica and B. pertussis to various antimicrobial peptides were tested, [4] B.
bronchiseptica exhibited significantly higher resistance to antimicrobial peptides
compared to B. pertussis. The resistance in B. bronchiseptica was presumably due to the
highly charged O-specific sugar side chains in its LPS [4]. It was suggested that antigenic
polymorphism in the lipopolysaccharides from human and animal isolates of B.
bronchiseptica may be due to differences in receptors of human and animal respiratory
tracts [107].
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Urease, a bvg repressed phenotype in B. bronchiseptica, has been another suggested
virulence factor which may be involved in intracellular survival of this bacterium [120].
However, urease expression did not have any effect on the ability of B. bronchiseptica to
colonize and persist in the mouse respiratory tract [121, 131].
Intracellular survival
Although B. bronchiseptica has been considered an extracellular pathogen, there have
been a number of reports that demonstrate the intracellular survival of this organism.
Guzman et al. demonstrated intracellular survival of B. bronchiseptica in mouse dendritic
cells, in vitro and speculated that intracellular survival in natural infections caused by this
organism, may lead to the chronicity of infection [62]. Intracellular invasion of B.
pertussis was dependent on Bvg + phenotype and induction of apoptosis in macrophages
was attributed to the adenylate cyclase toxin [5]. B. bronchiseptica induced macrophage
killing by bvg -regulated factors [5]. Also, Bvg mutants of B. bronchiseptica showed
significant survival advantage over wild type strains [5]. A study by Brockmeier and
Register on intracellular survival and cytotoxicity of B. bronchiseptica in swine alveolar
macrophages indicated that another temperature dependent regulatory mechanism, in
addition to Bvg, may play a role in adhesion and intracellular survival of this organism
[14]. However, cytotoxicity for swine alveolar macrophages was observed only in
infection with virulent bvg+ strains [14]. The differential survival of B. pertussis and B.
bronchiseptica in macrophages has been attributed to their differences in acid tolerance
[179]. In contrast to B. pertussis, B. bronchiseptica is insensitive to an acidic PH as low
as 4.5. The acidic environment of the phagolysosome contributes to increased
intracellular survival of this organism. A significant TH1 response observed after
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intranasal inoculation with B. bronchiseptica indicates that, there may be relevant
intracellular phases of this bacterium during the infection cycle [64]. Chhatwal et al.
suggested that, the expression of a temperature regulated acid phosphatase in B.
bronchiseptica played a role in intracellular survival [25]. Forde et al. characterized the
uptake and persistence of B. bronchiseptica in murine phagocytes using a
bioluminescence-based reporter system [51]. In this study, B. bronchiseptica was
mutagenized with a suicide vector carrying lux genes from Photorhabdus luminescens on
a mini- Tn 5 derivative [51]. B. bronchiseptica was internalized by professional
phagocytes in a dose-dependent manner and the bacterium survived intracelluarly for
four days when a critical population size (>500:1 multiplicity of infection) was present
[51]. This study also suggested that B. bronchiseptica may have an intracellular phase
during the infection cycle.
Diseases caused by B. bronchiseptica
B. bronchiseptica had been considered a respiratory pathogen of mammals since its
identification in 1910 [60]. The involvement of this organism has long been recognized in
diseases such as acute infectious tracheobronchitis in dogs, atrophic rhinitis in swine, and
respiratory infections of laboratory animals [60]. These diseases are mostly self- limiting,
but can be chronic and some times complicated by secondary invaders [6, 7, 60]. The
hallmark of infection by this organism is prolonged, efficient colonization of ciliated
epithelium of the respiratory tract [9]. The ability to interfere with ciliary function is an
important factor in pathogenesis of B. bronchiseptica infections [9].
Canine infectious tracheobronchitis, or kennel cough, is a highly contagious
respiratory tract disease, affecting dogs, that is characterized by acute onset of cough [6,
17

7, 8, 9, 188]. Studies on experimental and natural infections of B. bronchiseptica in
canines proved that this organism could be considered as a primary etiological agent in
infectious tracheobronchitis [8]. The infection leads to moist, hacking, productive cough
[7, 8, 9, 188]. Microscopic lesions were limited to the ciliated epithelial mucosa with
influx of polymorphonuclear cells being a prominent feature [9]. Bacterial colonization in
experimental studies reaches its maximum at seven days after aerosol exposure and slow
progressive clearance occurs thereafter [8]. Many infected animals can remain
asymptomatic and the disease is usually self- limiting [9, 33].
Atrophic rhinitis is an upper respiratory tract disease of pigs characterized by
degeneration and atrophy of nasal turbinate bones leading to visible distortion, and
shortening of the snout [60, 169]. B. bronchiseptica can cause moderately severe
reversible turbinate atrophy [48, 49, 162]. Dermonecrotic toxin production by B.
bronchiseptica is correlated with turbinate atrophy [113,162, 165]. Experimental
infections in gnotobiotic pigs implicated that the colonization with phase I cytotoxic
strains of B. bronchiseptica damages the nasal mucosa and predisposes to colonization
by toxigenic P. multocida that can lead to a more severe form of the disease [162, 165].
Two recent studies on co- infection with B. bronchiseptica and porcine reproductive and
respiratory syndrome virus (PRRS) strengthen the hypothesis that, B . bronchiseptica
infection can adversely affect the respiratory tract defense mechanism leaving animals
vulnerable to infection with secondary agents like P. multocida [15, 16].
There has been increased documentation of B. bronchiseptica respiratory tract
infections of cats [181]. Clinical and experimental studies have proved that B.
bronchiseptica can also be a primary respiratory pathogen in cats [84]. Laboratory
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animals, especially guinea pigs, rabbits and rats get respiratory tract infections with B.
bronchiseptica [60]. Infections can be insidious in such populations; seventy five
percent of the rabbits in a commercial rabbitry were infected naturally with B.
bronchiseptica without showing any disease [35]. B. bronchiseptica has also been
associated with respiratory tract infections in horses [26, 76 ]. Rats and mice have been
used as experimental animal models to study B. bronchiseptica pathogenesis [32, 33, 72,
117]. Intranasal infection with a subletha l dose of B. bronchiseptica leads to prolonged
asymptomatic colonization in mice and rats [117].
There are well-documented cases of B. bronchiseptica infection in human beings
[204]. They are usually associated with immunocompromised patients. In an extensive
review, Woolfrey and Moody concluded that the agents might be occasionally
encountered as a commensal of the respiratory tract and rarely as a pathogen in severely
immunocompromised patients [204]. Animal contact may or not be a recognizable risk
factor and nosocomial human to human transmission has been reported [176]. Infections
in immunocompetent children are also reported [177]
Immunity to B. bronchiseptica infections
Most naturally occurring B. bronchiseptica infections are localized to the respiratory
tract [6, 60]. Recovery from infection in dogs resulted in resistance to re- infection that
lasted for 6 months [6, 60]. Vaccination with formalin killed bacteria produced high titers
of serum agglutinins but did not prevent infection [7]. The dogs that recovered from
experimental infection and were maintained in isolation were resistant to a subsequent
aerosol challenge seven months after recovery. B. bronchiseptica specific sIgA in the
respiratory tract has been correlated with protection [11]. Killed, parenterally, inoculated
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whole-cell vaccines of B. bronchiseptica were successfully used to prevent death,
bronchopneumonia and carrier state in lab animals [60] and to protect swine from B.
bronchiseptica induced-atrophic rhinitis [60, 102]. A subcellular B. bronchiseptica
vaccine containing concentrated cell wall fractions provided greater protection in swine
than the whole cell vaccines [60]. A local immune response to Bordetella infection was
achieved by a live, avirulent intranasal vaccine, which induced early protection against
disease in swine and dogs. Intranasal immunization with live avirulent bacteria may
reduce clinical disease and duration of shedding and may induce some degree of
colonization resistance [7, 60]. Although some parenteral vaccines induced high levels of
agglutinating antibodies, they did not provide protection from diseases [60]. An acellular
extracted antigen vaccine protected dogs from disease and reduced shedding of B.
bronchiseptica [41]. In dogs, parenteral or intranasal B. bronchiseptica vaccines may
provide substantial protection from clinical signs of respiratory tract diseases,
administration of both types of vaccines, in sequence, provided greatest degree of
protection against the disease [41].
Gueirard et al. noted that colonization of lungs in BALB/c mice inoculated with a
live, virulent strain of B. bronchiseptica, increased during the first 10 days and decreased
thereafter [64]. A non-virulent strain in similarly inoculated mice, was cleared from lungs
by 6 days. In this study, a human isolate lacking adenylate cyclase was unable to induce
progressive infection of the respiratory tract of mice. Infection was also associated with
an influx of leukocytes into the respiratory tract. B. bronchiseptica-reactive serum IgG
and IgM were observed soon after infection, levels gradually increased for 14 days and
remained constant for 117 days. Much of the IgM production that was produced was not
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specific for B. bronchiseptica [64] perhaps due to triggering mechanisms unrelated to
specific epitope recognition. B. bronchiseptica specific IgA in serum was induced soon
after infection (14 days post-infection) and increased during the 117 days observation
period. A cellular immune response was demonstrated to B. bronchiseptica and adenylate
cyclase. High levels of IFNγ and IL 1-α detected in antigen- induced proliferation assays
indicated that a Th1 type of immune response was produced during B. bronchiseptica
infections. B. bronchiseptica infections were not accompanied by immunosuppression of
cellular response to mitogens [64].
Mattoo et al. established a correlation between presence of fimbriae and effective
tracheal colonization of B. bronchiseptica in mice and rats [117]. They demonstrated that
the majority of serum IgM generated following B. bronchiseptica infection in rats was
against fimbriae [117] and suggested that fimbriae might be involved in modulation of
the humoral immune response [117]. Neither serum nor mucosal IgA response was
detected in rats infected with B. bronchiseptica. It was postulated that absence of an IgA
response might have been due to antagonistic effect of toxins produced by the type III
secretion system [117]. This suggestion was supported by another study in which, mice
infected with type III secretion mutants, had higher titers of anti-bordetella antibodies
than mice infected with wild-type organisms [207].
Heterologous antigen expression in Bordetella spp.
Although there are several studies on expression of Bordetella antigens in E. coli,
very little is known about heterologo us antigen expression in Bordetella species. Suarez
et al. expressed pertussis toxin gene from B. pertussis in B. bronchiseptica [185]. Since
pertussis toxin is an essential component of acellular vaccines against whooping cough,
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the aim of their study was to overcome the problems associated with slow growth and
poor yields of pertussis toxin in B. pertussis, to facilitate improved industrial production,
and to avoid bio-safety concerns of handling a human pathogen like B. pertussis. They
constructed a chromosomal integrate of the pertussis toxin operon in B. bronchiseptica,
that would allow inducible production of pertussis toxin from a promoter responsive to an
aromatic inducer.
The first study on expression of a foreign protective antigen in Bordetella spp was
published by Renauld-Mongenie in 1996 [161]. This study explored the possibility of
using B. pertussis as a live mucosal vaccine vector for a protective antigen of
Schistosoma mansoni. A S. mansoni, glutathione S-transferase gene was fused to the
filamentous haemagglutinin gene of B. pertussis and the corresponding protein was
expressed on the cell surface of B. pertussis. A single intranasal inoculation of the
recombinant strain induced mucosal antibody to Schistosoma antigen (Sm28GST). This
was the first study to demonstrate the utility of recombinant respiratory pathogens for the
delivery of heterologous protective antigens. Later, in 1998, the same group of scientists
created an attenuated derivative of B. pertussis and showed that attenuation of pertussis
toxin resulted in an improved immune response to filamentous haemagglutinin and
Sm28GST [128, 129]. A single intranasal inoculation of this strain induced protection
against the parasite and protection against B. pertussis in mice. The ability of pertussis
toxin-deficient and wild-type Bordetella to induce antibody response at a distal mucosal
site was examined by Mielcarek et al. [128]. They observed that intranasal infection with
B. pertussis produced detectable antibodies in the genital tract. Although pertussis toxin
has been reported to have adjuvant properties, this study did not find any
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immunomodulating effect of pertussis toxin in inducing local antibody response [128].
Administration of purified FHA by the intranasal or intravagina l route could boost the
immune response generated at these sites. In another study by Mielcarek et al., priming
with recombinant B. pertussis expressing Sm28GST and subsequent intranasal boosting
with the foreign protein (Sm28GST) induced a systemic antibody response against the
foreign antigen [130].
The bioluminescence gene from P. luminescence has been expressed in B.
bronchiseptica and used to study the uptake and persistence of B. bronchiseptica in
murine phagocytes [51]. A mini- Tn-5 promoter probe carrying the intact lux operon from
P. luminescence was introduced into B. bronchiseptica and was used to create a pool of
bioluminescent fusion strains of B. bronchiseptica. This allowed measurement of light
output from the recombinant organisms witho ut the addition of exogenous substrate.
Purified recombinant, detoxified adenylate cyclase of B. pertussis has also been used
to deliver multiple epitopes from lymphocytic choriomenigitis virus and human
immunodeficiency virus to induce a cytotoxic T cell- mediated immune response in mice
[44]. The cell invasiveness and availability of permissible insertion sites are features of
adenylate cyclase that may be useful for induction of protective cell- mediated immune
responses against pathogens [44].
Advantages of mucosal immunization
The mucosal surfaces of the gastrointestinal, respiratory, and urogenital tracts
represent the major port of entry for several human and animal pathogens [118, 119].
Mucosal exposure to foreign antigens during infection often results in development of an
immune response. Therefore, mucosal immunization with specific vaccine antigens may
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be more effective for immunization against infections acquired through mucosal surfaces
[118, 119]. Mucosal immunizations offer several advantages compared to parenteral
immunizations [24, 118, 119, 143]. They can induce mucosal as well as systemic immune
responses and because of reduced direct contact with vaccine components in the systemic
circulation can increase vaccine safety [24, 143]. Easy administration of multiple
vaccines and reduced requirement for trained personnel make mucosal immunization
strategies attractive [24, 143].
Mucosal immune system
There are many non-specific defense mechanisms that play important roles at
mucosal surface. Mucus, acid, enzymes, bile, lysozyme, and lactoferrin secreted at the
mucosal surface can inhibit microbes [118, 119]. Peristaltic contraction of smooth
muscles, ciliary action of the epithelium, and tight junctions of the mucosal epithelium
can exclude microorganisms from the mucosal surfaces and prevent invasion into deeper
body tissues [103, 105, 118, 119]. Mucosal surfaces of gastrointestinal, respiratory and
urogenital tracts are covered by a single layer of epithelial cells, which face an
environment rich in pathogens. Some pathogens have developed effective mechanisms to
colonize and invade these surfaces and, in defense, mucosal tissues are heavily populated
with cells of the immune system [80, 103, 105, 118, 119]. The specialized sites where the
induction of mucosal immunity begins consists of organized mucosa-associated lymphoid
tissue called O-MALT and wide spread diffused mucosa-associated lymphoid tissue
called D-MALT [103, 105, 118, 119]. O- MALT occurs in tonsils, respiratory tract and in
gastrointestinal tract [103, 105, 118, 119]. Dendritic cells or specialized epithelial M cells
capture and sample antigens at the mucosal surface [103, 105, 118, 119]. Antigen
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sampling across the stratified epithelia of the oral cavity, vagina, and epithelium of the
upper airways is carried out by migratory dendritic cells, which carry antigens to local OMALT or to distal lymphoid tissue. Antigen sampling across the intestinal and bronchial
epithelia is carried out by M-cells that deliver antigen to local O-MALT [103, 140]. In
the airway epithelium, dendritic cells form a network with up to 700 dendritic cells /mm2
[103, 105, 118, 119]. They represent major histocomatibility complex class II bearing,
antigen-presenting cells of the airways and constitute the first line of defense against
inhaled antigens. In the bronchi and in the gastrointestinal tract, M cells transport
macromolecules, particles and microorganisms to the mucosal lymphoid follicles and
initiate a secretory immune response [103, 105, 118, 119]. Although uptake and sampling
of microorganisms by M cells lead to an immune response and eliminate mucosal
infections, some viruses and bacteria exploit M cells for gaining entry into the host [103,
105, 118, 119].
Both humoral and cellular immune responses are generated at mucosal surfaces [103,
105, 118, 119]. IgA is the major antibody seen at mucosal surfaces [105]. The surface
area occupied by mucosal epithelium in the body is enormous due to many macroscopic
and microscopic foldings; as a result it may not be too surprising that IgA is estimated to
be the most abundant immunoglobulin class found in the body (>50mg/kg
bodyweight)[105]. IgA blocks the attachment of infectious agents to mucosal epithelia
and provides an immune exclusio n barrier in secretions against microbial pathogens,
toxins, and other antigens [105, 139]. IgA can bind to lectin- like bacterial adhesins
through its carbohydrate moieties and may, in this fashion, also block bacterial adhesion
to receptors on epithelial cells. IgA also neutralizes viruses within the epithelial cells,
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excretes antigens from sub-epithelial compartments across the epithelium into secretions,
and activates complement through the alternate pathway [105].
IgA is secreted from plasma cells as dimers that bind to polymeric immunoglobulin
receptors (pIgR) on the basolateral surface of epithelial cells that line the mucous
membrane [105]. At the apical surface, proteolytic cleavage splits the external domain of
pIGR (secretory component) and releases the dimeric IgA-secretory component complex
(secretory IgA) into the mucosal secretions. In the secretions, IgA binds to antigens and
prevent them from attaching to or penetrating the mucosal surfaces [105, 139, 140].
Like IgA, pentameric IgM also plays a role in preventing mucosal infections. IgM
binds to the pIgR with less affinity than IgA [105]. IgG, the principle class of systemic
antibody, is also seen in mucosal secretions and may enter the mucosal surface through
diffusion. IgE also is considered to be a significant mucosal immunoglobulin [105].
Antibodies passively administered or actively induced at mucosal surfaces can protect
mucosal surfaces from infection and invasion of pathogens. The success of oral
vaccination for poliomyelitis and the abundant knowledge about mucosal immunity has
created great interest in mucosal vaccination against infections that gain entry through the
mucosal surfaces [105, 118].
Protein antigens applied to a mucosal surface can stimulate a mucosal immune
response with secretory IgA production, a systemic immune response with IgG or IgM or
development of mucosal tolerance with systemic unresponsiveness [103, 105, 143].
Tolerance is defined as loss of systemic immune responsiveness to that antigen following
mucosal exposure [143]. Tolerance may be due to direct inactivation of antigensensitized lymphocytes via clonal deletion or anergy [143]. Other factors such as
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interaction between regulatory and effector T cells, Th1 versus Th2 and γ/δ T cell
receptors, bystander suppression, and tolerogenic proteins may also be involved in the
induction of tolerance [143].
Vaccination strategies to induce mucosal immune response
Mucosal surfaces of the body are colonized with commensal bacteria, which may not
cause any harmful effect to the host, and the maintenance of this microflora is based on a
balanced immune response, which avoids an excessive overgrowth [78]. Even in
individuals that are fully immunocompetent, bacterial infections of the gastrointestinal,
respiratory and urogenital mucosa are among the leading problems in man and animals
[78]. Parenteral vaccines are generally not very effective for inducing an immune
response that prevents mucosal infections and they do not induce immune responses at
mucosal sites [78]. They are usually active against invasive systemic diseases [205]. As
already mentioned, stimulation of one mucosal site can lead to immune responses at
distal mucosal sites [205].
Stimulation of a mucosal immune response requires efficient delivery of vaccine
antigens to mucosal inductive sites. Often, enhancement of the immune response requires
co-administration of adjuvants [24]. In development of vaccines against mucosal
infections, it is important to define the nature of immune response that is required for
protection [118, 119].
Oral delivery of vaccines has been most widely studied because of the convenience of
vaccination through this route [173, 174]. Intranasal immunization will be advantageous
for the control of pathogens whose route of entry is the respiratory tract because the
magnitude of immune response produced will be maximum at this site [205]. Intranasal
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delivery of vaccines is more effective in inducing systemic and mucosal immune
response compared to other routes [205]. Mucosal immunizations with live organisms
that colonize the nasal cavity may induce strong, long lasting immunity after a single
inoculation [205]. Compared to oral vaccination, intranasal vaccination may have the
advantages of lower dose requirement, greater stability, and less competition from
colonizers [205]. Antigen will be taken up by the antigen presenting cells at the nasal
mucosa (mainly dendritic cells) and will be presented to underlying nasal associated
lymphoid tissue (NALT), where they induce a secretory IgA response [205], or the
trapped antigen will be carried to local draining lymph node to initiate a systemic IgG
response [105, 118, 205]. Recirculation and homing of memory immune cells through a
common mucosal system can induce antibody response at distant mucosal sites [205]. For
example, intranasal immunization with B. pertussis resulted in an antibody response at
the genital surface [129]. Compartmentalization of the common mucosal immune system
establishes a theoretic base for considering the best route to deliver mucosal vaccine
[205].
Delivery of antigens by the mucosal route is associated with major problems like poor
immunogenicity and susceptibility to degradation [123]. To overcome these problems,
strategies such as entrapment into biodegradable microspheres, liposomes, their
production by attenuated viral/ bacterial carriers or transgenic plants, or their
administration with mucosal adjuvants are being used [123].
A number of adjuvants enha nce the immunogenicity of antigens when delivered by
parenteral route. Only a few molecules such as cholera toxin produced by Vibrio cholerae
and heat labile toxin produced by Escherichia coli have been reported to act as mucosal
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adjuvants [39, 79]. The potential side effects of these toxins limit their use in vaccinations
[180]. Co-administration of cytokines and bacterial DNA containing unmethylated CpG
dinucleotide motifs have been shown to be effective as vaccine adjuvants [100, 123].
Non-living Antigen delivery systems
Controlled delivery systems of microparticles consisting of polyesters, polylactides
and glycolides are primary candidates for development of microencapsulated vaccines
[123, 127]. Vaccine antigens are incorporated either adsorbed or chemically bound to the
matrix [123, 127]. Incorporation of antigens into such microparticles protects the antigens
from degradation and facilitates uptake of antigen and antigen presentation that leads to
more efficient systemic and mucosal immune responses [123, 127]. The most important
limitations of using vaccine antigens in microparticles are: stability of the antigens, the
particle uptake, technical difficulties in delivery and associated toxicological issues [123,
127]. Liposomes are lipid vesicles formed when phospholipids are exposed to an aqueous
environment and can act as immunoadjuvants, protect antigens, and are considered safe
immunoadjuvants [123, 127]. Immunostimulating complexes (ISCOMS) are complexes
built up by cholesterol, lipid, immunogen, and saponin. Administration of ISCOMS
through parentral or mucosal routes can induce antigen specific immune responses [123,
127].
Live viral vectors
The natural ability of the viruses to infect target cells via specific entry mechanisms
can be utilized to deliver antigens to specific cell types for antigen presentation and
immunization [69]. The two types of basic live viral vectors used are attenuated viruses
and replication defective or host range restricted viruses [69]. Several viruses such as
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poxviruses and adenoviruses have served as vectors to deliver heterologous antigens.
Vaccinia virus is the most studied viral vaccine vector [69]. Attenuated strains of
Vaccinia virus expressing rabies virus glycoprotein have been used in field
immunizations to protect wild animals from rabies [69]. Administration of these vectors
to wild animal populations via polyurethane baits led to development of high neutralizing
antibody titers against rabies virus [69]. Another commercially licensed virus vaccine
vector in United States is fowl poxvirus that expresses glycoproteins of Newcastle
disease virus. This vector can protect poultry from fowl pox and Newcastle disease [69].
Adenovirus vectors that can be administered orally are receiving attention. A number
of antigens such as vesicular stomatitis virus glycoprotein, hepatitis B virus surface
antigens, herpes simplex surface antigens have been successfully expressed in adenovirus
vectors [69]. Herpes simplex virus, varicella zoster virus, poliovirus, simian
immunodeficiency virus are the other viral vectors under study [69]. Replication
defective mutants of poxvirus, adenovirus, and herpes simplex virus are now available
and are considered to be good vaccine vector candidates because of their increased safety
over wild-type and attenuated vaccine vectors [69]
Live bacterial vectors
Live multivalent vaccines using attenuated recombinant bacterial vectors have several
advantages. Many proposed live vectors are administered by the oral or respiratory routes
[124, 173, 174]. They are inexpensive to manufacture and, the live nature of the delivery
system and the danger signals provided might make weak tolerogenic antigens more
immunogenic [124, 173, 174]. Depending on the type of pathogenic mechanisms
employed by a live bacterial vaccine vector, an immune response could be generated
30

through TH1 or TH2 pathways [124]. The specificity of different vectors to colonize
different mucosal surfaces can be utilized to target an immune response at desired sites.
Live antigens that express foreign protective antigens in host tissues may result in longer
antigen presentation than non- living or parenterally administered preparations. Live
attenuated bacterial vectors expressing heterologous protective antigens hold several
attractive features compared to contemporary vaccines [124, 173, 175]. They are;
1)

Unlimited cloning capacity

2)

Effectiveness after single-dose vaccination

3)

No requirement for addition of adjuvant

4)

Non-invasive and easy administration procedure

5)

Potential for producing multivalent vaccines

6)

Low reactogenicity and low cost of production.

Additionally, antibiotic susceptibility allows an extra measure of safety to bacterial
vectors, which is an advantage over live viral vectors [124, 173, 174, 203]. Both
attenuated and commensal organisms have been successfully used as live vaccine
vectors and some of them are discussed below.
Salmonella are intracellular pathogens involved in many important diseases of
humans and animals. Following ingestion, salmonellae replicate in peyer's patches and
disseminate via the MALT to the systemic tissues. Such infection will lead to either
disease or broad-based immune responses that include systemic, mucosal, humoral and
cell- mediated immunity [173, 174]. Mutants deficient in synthetic pathways involved in
aromatic amino acid, purine, adenylate cyclase, and PhoP/PhoQ systems are well
characterized and are efficient carriers for antigens [173, 174]. A vast number of
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heterologous antigens have been expressed in attenuated salmonella including, bacterial,
viral and parasitic antigens, eukaryotic proteins and cytokines [43, 173, 174]. Functional
immune responses to these heterologous antigens have been demonstrated.
Chromosomal integration of the genes encoding an antigen leads to stable, low level
expression of the antigen. Plasmid mediated expression leads to high level expression
but can result in instability of the plasmid and toxicity to the bacterial host [43, 173,
174]. Nakayama et al. introduced balanced lethal vector systems in salmonella that were
characterized by the maintenance of multiple copies without the requirement of
antibiotic selection [53, 54, 186]. In these systems, a plasmid that carries a vital
metabolic gene which is deleted in the host bacterial strain will lead to positive selection
of the plasmid bearing strain. Genes for heterologous antigens can be incorporated on
the rescue plasmid. In addition, sub-cellular location [167], gene transcription, and
timing of expression in eukaryotic cells [77] may influence immunogenicity of the
antigen. Rapid advances in understanding of the molecular basis of pathogenesis of
salmonella species have resulted in development of several candidate vaccine vector
strains [23, 173, 174]. Recombinant Salmonella typhimurium strains evoked local as
well as systemic immune response to heterologous antigens by oral, nasal, rectal and
vaginal routes of immunization [82].
BCG (Bacillus Calmette Guerin), an avirulent derivative of Mycobacterium bovis, is
widely used as a vaccine against tuberculosis in human beings [144]. While the slow
growth rate of Mycobacterium species has impeded research, there have been
tremendous developments like the discovery of shuttle plasmids (plasmids that can
replicate in Mycobacterium and E. coli), gene replacement technology based on
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homologous recombination with M. smegmatis, and antigen secretion systems [144].
Augmentation of immune responses by the well-known adjuvant activity of BCG is also
an advantage. BCG has been engineered to express a variety of heterologous antigens.
They include proteins from human immunodeficiency virus, tetanus toxin,
pneumococcal surface protein, pertussis toxin and parasite antigens like schistosoma,
leishmania, or plasmodium antigens [144]. BCG that secretes immunostimulatory
cytokines have been made and tested as anti-tumor agents [144]. Since a large
proportion of human beings are already immunized with BCG, the use of BCG that
expresses heterologous protective antigens for control of tuberculosis and other common
diseases may be realized soon.
Vibrio cholerae is a Gram-negative organism responsible for the disease, cholera.
This is a non- invasive organism that induces potent long- lasting mucosal and systemic
immune responses [69, 171]. The ability of this organism to adhere to the M cells has
been utilized for vaccine antigen delivery to the gastrointestinal tract [69]. Attenuated
strains that lack cholera toxin have been used to induce mucosal and systemic antibody
responses to heterolo gous antigens [69, 171].
B. pertussis has been studied as a mucosal vaccine vector directed to the respiratory
tract. The glutathione transferase gene from Schistosoma mansoni was integrated into the
filamentous hemagglutinin gene of B. pertussis and was expressed [161]. A single
intranasal immunization with the recombinant B. pertussis lead to immune responses to
the Schistosoma antigen as well as to B. pertussis [161]. Brucella spp have also been
considered as possible vectors for intracellular delivery of antigens [28].
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Mucosal inoculation with recombinant Gram-positive bacteria such as Streptococcus
gordonii and certain strains of Lactobacillus, which are among the endogenous
microflora, have also been used to deliver heterologous antigens [155, 168].
Streptococcus gordonii, originally isolated from the oral cavity of humans, is capable of
colonizing the oral cavity and vagina of mice. A number of antigens have been expressed
in S. gordonii by replacing the sequences encoding the surface exposed domains of the
M6 protein with foreign genes of interest [155] The secretion signal and cell wall
anchoring domain of the M6 protein served to direct the export of the antigen to the
surface. The foreign proteins expressed in S. gordonii were integrated into the
chromosome by homologous recombination so that genes were stably maintained in the
chromosome in vivo without any antibiotic selection.
Nonpathogenic staphylococcal species such as S. xylosus, and S. carnosus, which are
widely used in meat fermentation processes, have been developed as live bacterial
vectors [175]. High copy number shuttle vectors were advantageous in that they
provided multiple copies of the foreign gene per cell. In these systems, the promoter,
signal sequence and propeptide sequence from the S. hyicus lipase gene were utilized to
achieve translocation through the cell membrane. However, large number of
immunizations and surface display of heterologous antigens were necessary for
induction of an immune response [175].
Lactococcus lactis a Gram-positive bacterium used in industry is non- invasive, nonpathogenic and does not colonize the mucosal surface. Researchers have exploited the
microparticle nature of this bacterium in heterologous antigen delivery [19]. Several
antigens have been expressed in Lactococcus using an inducible T7 RNA polymerase
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system or the pTREX series of constitutive expression plasmid. When applied via a
mucosal route, mucosal as well as systemic immune responses were noticed in mice.
Lactobacillus, a Gram-positive bacterium that is prominent in human indigenous
gastrointestinal flora, has been used to express heterologous antigens from plasmid
vectors and following chromosomal integration [168]. The potential for induction of
immunological tolerance to foreign antigens has to be considered when utilizing
commensal bacteria as vaccine delivery vehicles. At present, the relationship between
normal flora and the host immune system is very unclear [168]. Listeria monocytogenes,
a facultative intracellular Gram-positive pathogen, is a promising vaccine carrier for
evoking a cellular immunity [65]
There are potential problems associated with the use of live bacterial vectors.
Reversion to virulence is one of the major concerns associated with live bacterial vectors.
Stability of attenuated phenotypes should be ensured by careful inactivation of target
genes; single gene inactivation is less desirable [18, 53, 124]. Due to preexisting
immunity, the vaccine dose required to trigger immune responses in endemic areas and
nonendemic areas may differ. Medina et al. suggested that presentation of the vaccine in
different formulations according to geographic area might solve this problem [53, 124].
The use of plasmids for expression of foreign genes may lead to plasmid instability and
loss of antigen expression [18, 53, 124]. The presence of additional genes such as
antibiotic markers used for positive selection is not desirable [124]. The use of low copy
number plasmid vectors containing killing systems, partition function and non-antibiotic
selection markers are advisable. Integration of a foreign gene into the chromosome of the
host strain may lead to low level expression from a single copy gene and be insufficient
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to generate an effective immune response [18, 53, 124]. Another strategy, which may be
effective, is the use of in- vivo activated promoters [124]. The expression of particular
vaccine antigens by non-pathogenic commensal or environmental organism may enhance
their virulence in human or animal populations, and increase the environmental risk.
Also, horizontal gene transfer from vaccine strains to mucosal flora or environmental
organisms may pose a threat [124]. This can be prevented by incorporating conditional
lethal systems [38, 136]. Prior exposure to the antigen carrier can compromise the
efficacy of a vaccine candidate. As reported in salmonella, [3] utilization of different
carrier strains or bacterial serotypes for preparation of vaccines or allowing an established
optimal window for readministration of vaccine may eliminate this risk [124]. Host
genetic factors may also modulate the type of immune response [124]. Diversity in MHC
genes, and presence or absence of some genes associated with immune system can lead to
differences in the type of immune responses generated [124]. It is also important to have
proper balance between attenuation and immunogenicity. The dissemination of live
attenuated microorganisms in the field may pose a risk of disease, especially in
immunocompromised individuals and require stricter safety guidelines [69]. Vectors that
are highly susceptible to antimicrobial agents are most desirable.
Conclusion
Vaccination constitutes the most cost effective tool for the prophylaxis of infectious
diseases. Most patho gens gain entry into the body through the mucosal surfaces. So
administration of immunogens through the mucosal route and induction of immune
responses at these sites are essential. Delivery of vaccine antigens by bacterial carriers
has resulted in effective humoral and cell mediated immune responses. The potential
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value of live bacterial vectors for vaccination purposes was recognized by the World
Health Organization (190). B. bronchiseptica, effectively colonizes the respiratory tract
of mammals, and is an ideal candidate as a mucosal vaccine vector. Application of this
system in the disease, atrophic rhinitis, is a rational approach to refining existing vaccines
and could be expanded to control other diseases in animals.
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Isolation and characterization of a promoter useful for
heterologous antigen expression in Bordetella
bronchiseptica using a green fluorescent protein reporter
system
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Abstract
Bordetella bronchiseptica, an adept colonizer of the upper respiratory tracts
of mammals, may be selectively utilized as a live bacterial vector to deliver protective
antigens to the respiratory tract. Promoters and conditions for optimal expression of
foreign antigens in B. bronchiseptica have not been determined. In this study, a B.
bronchiseptica promoter region (P9) related to heat shock protein genes was identified
using a green fluorescent protein (GFP) reporter system. The region identified has 98%
homology to the cpn10/60 gene of Bordetella pertussis. The efficiency of this promoter
to drive GFP expression was analyzed and compared in four B. bronchiseptica strains
using flow cytometry. GFP expression from the P9 promoter was also compared to that
of a B. bronchiseptica fimbrial gene (fim N) promoter and Escherichia coli derived tac
promoter. The P9 promoter had the highest level of activity in all B. bronchiseptica
strains tested under normal laboratory incubation conditions using common media. The
tac promoter was more active in E. coli than in B. bronchiseptica. The fim N promoter
had low level activity, detectable only in bvg positive strains of Bordetella
bronchiseptica. The P9 promoter may be a good candidate for expression of
heterologous antigens in this species. In addition, B. bronchiseptica constructs with
strong constitutive expression of GFP may be useful to characterize the adherence and
colonization of this bacterium.
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Introduction
Bordetella bronchiseptica is a respiratory pathogen, which infects a wide variety of
host species including domestic, laboratory and wild animals and may opportunistically
infect humans [4, 14]. B. bronchiseptica can express a battery of adhesins, like fimbriae,
filamentous haemagglutinin, adenylate cyclase and pertactin that enable it to colonize the
upper respiratory tract of various host species [10]. The ability of this organism to
efficiently colonize the respiratory tract may be utilized to deliver protective antigens
from other pathogens to the respiratory tract. Intranasal inoculation with B.
bronchiseptica has been shown to induce long lasting humoral and cellular antibody
responses in mice [15]. Mucosal application of vaccines induces immune responses at
systemic and mucosal sites [24, 28]. A single intranasal inoculation of mice with B.
pertussis expressing a Schistosoma antigen was able to induce mucosal antibody
responses in the respiratory tract as well as at other mucosal sites [25, 26, 32]. Compared
to the oral route of immunization, intranasal vaccine application may have the advantage
of low dose requirement, greater stability and less competition from colonizers [42]. Live
bacterial vectors, which can colonize the respiratory tract, are attractive candidates for
this purpose [28].
Many virulence genes in the genus Bordetella are controlled by a two-component
signal transduction system encoded by the bvg locus. The proteins produced by this
locus, BvgA and BvgS, are responsible for phenotypic modulation in response to
environmental signals like temperature and certain chemicals [10] and, the promoter
region of this operon contains a cytosine repeat region that is subject to frequent
mutations [3]. The significance of the bvg locus in infection and the effect of in vivo
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conditions on its expression are not completely understood. Therefore, to study
heterologous antigen expression, a strong promoter was sought that could drive
constitutive expression of genes in B. bronchiseptica
In this study, a B. bronchiseptica promoter region (P9) related to heat shock protein
genes was identified utilizing a promoter-probe vector carrying a promoter- less green
fluorescent protein gene. This promoter induced high level expression of GFP in four
different strains of B. bronchiseptica and was compared to GFP expression from the
Escherichia coli derived tac promoter and a bvg regulated fim N gene promoter [17]
under common laboratory conditions. B. bronchiseptica expressing GFP from P9
promoter was utilized to study in vitro adherence to Vero cells and colonization of mouse
respiratory tract.
Materials and methods
Plasmids, bacterial strains, and enzymes
The origin of B. bronchiseptica strains has been previously described [6]. Strain 55 is
a live attenuated B. bronchiseptica (ATCC 31437) vaccine strain. The INVF', (Invitrogen
Inc., San Diego, CA) is a lac represser gene deficient Escherichia coli strain. All bacteria
were grown in Luria Bertani (LB) agar or broth with appropriate antibiotic selection at
37o C unless otherwise indicated. Restriction enzymes and Taq polymerase were products
of PANVERA, Madison, WI. Wizard plus SV miniprep kit (Promega, Madison, WI) was
used for plasmid isolation. The plasmid, pBBR1MCS2, (kindly provided by Michael E.
Kovach) was used for all cloning purposes [20]. The plasmid pBBR1-KGFP (kindly
provided by Stephan Kohler) was used to obtain the gfpmut3 gene [9, 19].
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DNA manipulation
All polymerase chain reactions were performed in a Gene Amp PCR system 9600
(Perkin Elmer, Narcross, GA). A 30-cycle program consisted of denaturing at 95o C for
1.5 minutes, annealing at 50o C for 30 seconds, and extension at 72o C followed by a last
cycle of 5 min extension at 72o C. All primers used for PCR amplification were designed
to contain restriction enzyme sites (underlined).
Promoterless gfpmut3 gene was amplified from pBBR1-KGFP by PCR using forward
primer 5'-CGGGATCCGATGAGTAAAGGAGAAGAA-3'and reverse primer
5'-CGGAATTCTTATTTGTACAATTCATCC-3' and cloned into the BamHI and EcoRI
sites of pBBR1MCS2. The resulting plasmid was designated as pBBRGFP.
Chromosomal DNA was isolated from B. bronchiseptica strain 110H using Easy DNA
kit (Invitrogen Inc., San Diego, CA). It was digested with Sau3A1 and electrophoresed
on an 8% agarose gel. DNA fragments ranging from 0.25-3kb were purified from agarose
gel using Quiagen gel purification kit (Quiagen Inc., Valencia, CA) and ligated to BamHI
digested, calf intestinal alkaline phosphatase (New England Biolabs., Beverly, MA)
treated pBBRGFP. The ligation mixture was electroporated into B. bronchiseptica strain
110NH (Bvg-, avirulent phase) using a CELL-PORATOR Electroporation System
(GIBCO-BRL., Gaithersburg, MD) following the manufacturer’s instructions. This strain
was used to avoid the selection of bvg-regulated promoters. The electroporants were
isolated on LB agar containing kanamycin (100µg/ml). After 3 days of incubation at
37o C, cell suspensions from individual colonies were examined with a fluorescence
microscope (Nikon FLUOPHOT, Garden City, New York) equipped with blue
wavelength (375-490 nm) excitation filter and a 510nm barrier filter. The tac promoter
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was amplified from pGEX-5X-1 (GST gene fusion expression vector from Pharmacia
Biotech. Piscataway, NJ), using forward primer 5'-GGTCTAGACTGCACGGTGCACC3' and reverse primer 5'-CGGGATCCTGTTTCCTGTGTGA-3' and cloned in to XbaI
and BamHI sites of pBBRGFP. The resulting plasmid was designated as pBBRTACGFP.
To construct a plasmid expressing GFP under the control of fim N promoter, the GFP
gene was amplified with the same forward primer used for constructing pBBRGFP and
the reverse primer, 5'-CGGGATCCTTATTTGTACAATTCATCC-3' and cloned into a
unique BamH I site in the fim N gene in PCR2-FIM (11). This construct was amplified by
a primer specific to the 5' region of fim N (5'GGAAGCTTGCCATCACCAACTTATGTG-3') and the same GFP reverse primer used
for cloning pBBRGFP and cloned into the Hind III and EcoR I sites of the pBBR1MCS2
to obtain plasmid pBBRFIMGFP. All recombinant plasmids were electroporated into B.
bronchiseptica strains 110H, 110NH, R5 and Strain 55.
Growth curve
Bacterial growth curves were determined for each strain in LB broth, Brucella broth
and Stainer Scholte broth (SS broth) [35]. Each medium (10ml) was inoculated with
0.5ml of overnight culture of the B. bronchiseptica strains carrying recombinant plasmids
at 1:20 dilutions and incubated at 37o C in a rotary shaker (220rpm). At selected time
points 200µl of the culture was transferred to duplicate wells of 96-well microtiter plates.
The plates were read at an optical density of 592nm on an ELX800 ELISA reader (BIOTEK instruments Inc., Winooski, VT).
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Flow cytometric analysis
Bacteria containing the recombinant plasmids were grown in LB broth, Brucella broth
or SS broth to late log phase at 37οC and 220 rpm. One ml of the culture was pelleted by
centrifugation at 14,000 rpm for 1minute. The pellet was washed 2 times in phosphate
buffered saline (PBS) and suspended in PBS to an approximate OD590 of 0.2. Bacterial
suspensions were analyzed in a FACSVantage SE (Becton &Dickinson, San Jose, CA)
equipped with argon laser exciting at 488nm and emitting at 540nm. Forward versus side
light scatter was used to gate the bacteria and the data was collected using logarithmic
amplifiers. A total of 10,000 events were acquired for each sample. The mean
fluorescence intensity for each sample was determined by using CELLQUEST analysis
software(Becton &Dickinson, San Jose, CA). B. bronchiseptica strains harboring plasmid
pBBRGFP were used as negative controls.
Adherence assays
Bacterial adherence to Vero cells was evaluated as previously described (17) with
modifications. B. bronchiseptica strain 110H (Bvg + virulent phase) and 110NH ( Bvgavirulent phase) were compared. Individual colonies from a 48 hr culture on LB agar
were suspended in PBS to obtain an OD590 of 0.1 (2.5x10 8 CFU/ml). One ml of this
suspension was mixed with a one ml suspension of Vero cells containing 1x10 6 cells/ml.
This mixture was incubated for one hour at 37οC with gentle mixing. The suspension was
centrifuged at 1000x g for 10 minutes to remove non-adherent bacteria. The resulting
pellet was washed twice in Hanks Balanced Salt (HBS) solution and suspended in 1ml
HBS. Adherence of recombinant B. bronchiseptica to Vero cells was measured by flow
cytometric analysis as described above.
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In vivo plasmid stability
BALB/C mice (4-6 weeks old) were purchased from Harlan Laboratories
(Indianapolis, IN) and were maintained by routine procedures in an AALAC accredited
laboratory animal facility. Mice were inoculated with 50µl of bacterial suspension in
PBS containing approximately 1x10 5 CFU of B. bronchiseptica 110H harboring
PBBRP9GFP. Mice were anaesthetized with Isoflurane (Abbot Laboratories, North
Chicago, IL) and 25µl of the bacterial suspension was instilled into each nostril. Mice
were sacrificed at 3, 6, 12, and 24 hours after inoculation. The lungs and trachea were
collected and fixed in 4% paraformaldehyde for 2hrs. The slow freezing protocol as
described previously [34] was followed. Briefly, after fixation, the tissues were washed
in PBS, embedded in Tissue-Tek O.C.T. (Miles Inc, Elkhart, IN) and stored at 4o C for
24 hours. The tissues were transferred to a slow freezing container with isopropyl
alcohol and allowed to freeze to -70o C. Sections were cut on a cryomicrotome
(Minatome- Damon /IEC division, Needham Heights, MA), mounted in PBS and
examined in a Leica SP2 laser scanning confocal microscope using 488nm argon laser
line for excitation and a spectral setup for GFP to collect emission.
Results
Identification and characterization of promoter
A library of clones containing fusions with the gfp gene and chromosomal DNA of
B. bronchiseptica 110H was constructed. A Bvg- avirulent phase B. bronchiseptica,
strain 110 NH, was used for promoter selection to avoid selection of bvg-regulated
promoters. From 2500 clones examined by fluorescence microscopy, one was identified
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which expressed GFP. The bacteria expressing GFP were bright green, when examined
by fluorescence microscope (Figure 1, appendix). Upon restriction digestion of that
clone, it was determined that the chromosomal DNA upstream to the gfp gene was
approximately 3kb. Restriction analysis was performed using enzyme sites within the
multiple cloning sites of pBBR1MCS2, flanking the gfp gene, to further reduce the size
of the insert. The gfp gene with the cloned upstream promoter region was digested with
EcoRV and EcoRI and the resulting 1.25 kb fragment was subcloned into the respective
sites of pBBR1MCS2 to obtain pBBRP9GFP. This plasmid was used in all downstream
experiments and the promoter region was designated as P9.
DNA sequencing (University of Tennessee, DNA sequencing facility) was
performed in the region immediately upstream of the gfp gene. A BLAST search of
~250 bp of the sequence, identified this region as having 98% identity to the
cpn10/cpn60 gene of B. pertussis [13]. There was a four base pair difference in the
region immediately upstream to the -35 sequences. The gene fragment upstream to the
gfp gene was an in frame fusion of sequence encoding the first 36 amino acids of the
cpn10 homolog gene, along with its corresponding regulatory sequences. The predicted
fusion protein contained a 4kd fragment of CPN 10 protein and intact GFP. As observed
previously in B. pertussis, this region contains sites for σ 32 and σ 70 as well as a CIRCE
(Controlling inverted repeats of chaperonin expression) element [13].
The plasmids pBBRP9GFP, pBBRFIMGFP, and pBBRTACGFP were
electroporated into B. bronchiseptica strains 110H, 110NH, R5, Strain 55 and to E. coli
strain INVF'. All strains of B. bronchiseptica with pBBRP9GFP showed strong green
fluorescence when examined by fluorescence microscopy; whereas, the fluorescence
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intensity was much lower in E. coli that harbored this plasmid. E. coli organisms
carrying PBBRTACGFP were brighter than all B. bronchiseptica strains with the same
plasmid. B. bronchiseptica strains carrying pBBRFIMGFP had the lowest fluorescence.
Neither the B. bronchiseptica strain, 110NH, nor E. coli harboring this plasmid had any
detectable green fluorescence.
The efficiency of P9, fim N and tac promoters to drive GFP expression was
quantitated using flow cytometric analysis. LB broth, Brucella broth and SS broth were
used for growing bacteria. A histogram showing flow cytometric profiles of fluorescence
intensity from different promoters in B. bronchiseptica strain 110H is shown in Figure 2.
All B. bronchiseptica strains consistently expressed very high levels of GFP from P9
promoter. There was no significant difference in expression of GFP between these
strains; however, the activity of this promoter was 40-50 fold lower in E. coli than in B.
bronchiseptica (Figure 3). In E. coli, tac promoter driven fluorescence (X=20) was 2-5
fold higher than in B. bronchiseptica strains (X=2.5-10) harboring the same plasmid. The
fim N promoter had low level activity in B. bronchiseptica strains110H (X=2.5), R5
(X=2.5) and Strain 55 (X= 4.23). However, unlike the P9 and tac promoters, the fim N
promoter was not active in strain 110NH (X= 1.6) and in E. coli (X=1.9). The intensity
of fluorescence measured by FACS analysis of B. bronchiseptica and E. coli cultures
expressing GFP under the P9 and TAC promoters was the same with each growth
medium tested. However, when cultivated in SS broth, B. bronchiseptica strains 110H
(X= 6.3 vs 2.5), R5 (X=5.3 vs 2.5) and Strain 55 (X= 6 vs 4.23) had increased levels of
GFP expression from the fim N promoter when compared to GFP expression in LB broth.
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There was no increase in GFP expression from fim N promoter in strain 110NH when
grown in SS broth.
Since heat shock proteins are induced during periods of stress, the effect of stress
stimuli on GFP expression from the P9 promoter was examined. Heat shock experiments
were performed as described previously [38]. For all strains, the GFP expression at 25o C
was 4-5 times lower than at 37o C. However, increasing the temperature from 25o C to
37o C and 25o C to 42o C for 20 minutes did not have any effect on GFP expression. Also,
addition of hydroge n peroxide at a final concentration of 0.005 % did not have any effect
on GFP expression.
Adherence assay
Adherence assays were characterized based on GFP expression from the P9 promoter.
Vero cells with adherent bacteria were examined by fluorescence microscopy and flow
cytometry. Consistent with our previous observation [17], using a conventional adherence
assay, the Bvg +, virulent phase strain, 110H, adhered well to Vero cells (Figure 4) but
Bvg-, avirulent phase, strain 110NH did not. Quantitation of the mean intensity of
fluorescence by FACS analysis showed that strain110H adhered 7-13 times more than the
avirulent phase, strain 110NH (Figure 5).
Plasmid stability and growth rate
The expression of GFP in overnight LB broth culture was exa mined with and with out
antibiotic selection. All strains of B. bronchiseptica expressed equivalent levels of GFP
from the P9 promoter under selective and non-selective conditions. In vitro stability of
pBBRP9GFP was tested by continuous passage of the bacteria in non-selective medium
(Tryptic Soy Agar). When bacteria were examined by fluorescence microscopy, all four
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strains of B. bronchiseptica failed to sustain the fluorescence after five passages at 48hour intervals (~10days) in non-selective medium. This loss of GFP expression was
associated with plasmid loss, since the recombinant organism could not be recovered in
antibiotic selection media. The plasmid was very stable in E. coli, showing green
fluorescence even after 10 repeated passages on non-selective agar medium. There was
no difference in growth rate of B. bronchiseptica strains expressing GFP compared to the
wild-type organisms (Figure 6) indicating that GFP expression did not have any adverse
effects on bacterial growth. The growth curves were similar for 110H, 110NH and R5;
whereas a longer lag phase was observed for Strain 55. All strains also had a longer lag
phase in SS broth than in LB broth or Brucella broth. At 3 hrs post inoculation, GFP
expressing bacteria were visualized in cryosections of the lung and trachea by confocal
microscopy. Green fluorescent bacteria were adherent to the ciliated epithelium of the
trachea and bronchioles (Figure 7). In alveolar spaces bacteria were associated with cells,
probably macrophages, but were not seen free in the lumen. At subsequent time periods
after 3hr, fluorescent bacteria were not detected in respiratory tracts of mice that had been
inoculated with B. bronchiseptica 110H harboring pBBRP9GFP.
Discussion
This report describes the identification and characterization of a promoter useful for
heterologous antigen expression in B. bronchiseptica utilizing a green fluorescent protein
reporter system. GFP has been successfully utilized as a reporter gene in several species
of bacteria [19, 29, 36, 37, 38]. GFP expression in prokaryotes is becoming a widely used
and easy tool to study various aspects of development, metabolism, gene expression and
pathogenesis [36, 37]. This is the first report of utilizing this system in B. bronchiseptica.
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In the related species, B. pertussis, GFP expression for the study of phagocytosis was
more efficient than tagging the organism with FITC [40].
Bacterial heat shock proteins are abundantly produced throughout the life cycle of
most bacteria and their synthesis is often increased during periods of stress [21]. In B.
pertussis the CPN 60 protein exhibits immunological and structural similarities to GroEL
protein of E. coli, which functions as a molecular chaperone [5, 7]. Complete cloning and
inactivation of the cpn10/60 homolog gene has to be done to understand the exact
function of this protein in B. bronchiseptica. However, this study demonstrates the utility
of this promoter region in heterologous antigen expression. Under normal laboratory
incubation cond itions, using common media, there was high level expression of GFP
from the P9 promoter. Stimuli required for P9 promoter activity have not been identified.
As reported in E. coli [1], it is possible that heterologous protein expression may itself act
as a stimulus for promoter function. Recent studies indicated a role of CIRCE element as
a negative regulator involved in inducing stress response [27, 44]. As suggested by Weiss
et al. [13], one speculation about the presence of binding sites for both σ 70 and σ 32
subunits is that organisms may switch these promoter regions under stress and non-stress
conditions. HSP promoters have been useful in heterologous antigen expression and
immunogenicity studies with a number of bacteria [3, 38]. In spite of the concern that use
of HSP as a vaccine component might lead to the generation of an autoimmune response
due to the highly conserved nature of HSP's among eukaryotes and prokaryotes,
microbial HSP's have been successfully employed as carrier molecules for peptide
immunization [43]. The binding affinity of HSP's for peptides and their involvement in
antigen processing may enhance specific immune responses [43]. The mucosal immune
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response to heterologous antigens expressed in B. bronchiseptica from the P9 promoter
and the effect of the remaining 4kD CPN peptide in the P9 promoter-GFP fusion awaits
further study.
The E. coli based promoter tac is widely used in E. coli expression systems. In this
study, GFP was expressed constitutively from this promoter since the E. coli strain we
used, and B. bronchiseptica do not possess a lac repressor gene. The tac promoter has
previously been utilized in B. bronchiseptica to study the expression of adenylate cyclase
toxin [22]. Although, the level of expression of GFP from the tac promoter in B.
bronchiseptica was much lower than that from the P9 promoter, heterologous antigen
expression from tac may have value in inducing an in vivo immune response. It was
observed in a Vibrio cholerae based heterologous antigen expression system that, the tac
promoter was better suited for generation of an in vivo immune response than both a HSP
promoter and an iron regulated promoter [16].
This study is the first to demonstrate functional activity of the fim N promoter in
B. bronchiseptica. This newly reported fimbrial gene sequence variant has serologic cross
reactivity with serotype 2 fimbriae of B. pertussis [17]. The reason for low- level
expression of GFP from fim N promoter is currently unknown. The length of cytosine
residues (C-stretch) in the promoter region plays a role in optimal transcription of bvgregulated genes [34, 41]. The fim N gene cloned in E. coli has two less cytosine residues
than its chromosomal counterpart [17]. Manipulation of the C-stretch may be another
strategy to improve the expression of proteins from this promoter. Surface expression of
heterologous antigens may have great advantage in improving antigen presentation and
immune responses. Live bacterial vectors and their adhesins are attractive candidates for
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improving mucosal vaccination strategies [28]. Among B. bronchiseptica adhesins,
fimbriae are shown to have immunomodulatory effects following intranasal inoculations
in mice [23]. The molecular chimerization of fim N with a Mannheimia haemolytica
leukotoxin fragment induced enhanced leukotoxin neutralizing antibody response in mice
immunized with this recombinant protein [30]. A recent report described the advantage of
over expression of a protective antigen as a novel approach to improve vaccine efficacy
[38]. The P9 promoter could be utilized to express fusion proteins of FIM N with other
protective antigens. Since fimbrial proteins are abundantly produced on bacterial
surfaces, chimeric fimbriae expressing epitopes from different pathogens seem to be an
attractive strategy for vaccine delivery. Host species specificity of fimbriae could be
selectively utilized to deliver antigens to a target species [6]. Two recent studies show the
effectiveness of B. pertussis fimbriae as a carrier protein for conjugate vaccines [11, 31].
There was an increase in expression of GFP from the fim N promoter, when cultivated
in SS broth, a commonly used medium for vaccine preparation [35]. A similar increase in
expression of filamentous haemagglutinin when cultivated in SS broth was recently
reported [18]. The potassium, sodium and chloride ion content of this mineral salts
medium may be upregulating the Bvg-controlled fim N promoter [10].
The original pBBR1, a broad host range cryptic plasmid isolated from B.
bronchiseptica [2], was stable without continuous antibiotic selection in Brucella species
in vitro for >10 days and in vivo in mice for >4weeks [8, 12]. In this study, GFP
expression from P9 promoter was used as an indicator of in vitro plasmid stability. The
pBBRP9GFP plasmid was maintained at high to moderate levels for only 4-5 passages
(10 days) in all the strains tested in the absence of antibiotic selection. Although PBBR1
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was originally isolated from B. bronchiseptica, the genetic modifications made on the
pBBR1MCS2 from the original plasmid or hetrologous antigen expression, itself, may
affect plasmid stability. It is noteworthy that there was no difference in GFP expression
from these recombinant strains over a period of 24 hours at 37o C under selective and
nonselective in vitro conditions as measured by FACS analysis.
GFP expressing bacteria were not seen in cryosections of the lung and trachea after 3
hours post inoculation. This might be the result of in vivo plasmid instability or
repression of the promoter function. The manipulation and processing involved in
preparing the tissue might have affected the sensitivity of the assay. A modified
construct, which can stably express GFP, could be utilized for pathogenesis studies
including the possible long term intracellular survival of this organism. In a subsequent
study with recombinant B. bronchiseptica that expressed another heterologous antigen
from the P9 promoter in pBBR1MCS2, only 6.5 % of the total bacteria recovered from
lungs and trachea of mice retained resistance to the selective antibiotic marker,
kanamycin, at 24 hours post inoculation, while colonization of plasmid-cured B.
bronchiseptica continued as long as 56 days post inoculation. Thus, improved plasmid
stability or construction of chromosomal co-integrates may be required to generate an
effective immune response to heterologous antigens.
The adherence assay utilizing FACS analysis of GFP expression from the P9
promoter is a more rapid and convenient way of quantitating adherence as compared to
conventional techniques. Since the adherence of B. bronchiseptica is an important
virulence property, this assay could be effectively utilized to compare the virulence of
different strains or to evaluate immune responses to vaccine preparations by attachment
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inhibition assay. In conclusion, the promoters characterized in this study, may be useful
for expression of different protective microbial antigens in B. bronchiseptica. The
potential for utilizing B. bronchiseptica as a mucosal vaccine vector is currently under
investigation.
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Figure 1
B. bronchiseptica strain 110NH expressing GFP from P9 promoter. Visualized by
fluorescence microscopy. Magnification X1000.
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Figure 2
Flow cytometric profiles of GFP expression in B. bronchiseptica strain 110H harboring
different recombinant plasmids. (A) pBBRGFP (promoter-less), (B) pBBRP9GFP (P9
promoter), (C) pBBRFIMGFP (fim N promoter), (D) pBBRTACGFP (tac promoter).
Intensity of the fluorescence on the x-axis indicates the level of GFP expression. X =
Mean fluorescence intensity.
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Figure 3
Comparison of GFP expression from P9 promoter in four different strains of
B. bronchiseptica and E. coli. The cultures were grown in LB broth and processed as
explained in materials and methods for flow cytometry. The intensity of GFP expression
from each strain is represented by mean fluorescence intensity as calculated by
CELLQUEST Software. B.bronchiseptica strains harboring pBBRGFP were used as
negative control
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Figure 4
Fluorescence microscopic image of Vero cells with adherent bacteria.
Vero cells were treated with B. bronchiseptica 110H harboring pBBRP9GFP and
visualized by fluorescence microscopy. Magnification X1000.
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Figure 5
Bar graph showing the level of adherence of B. bronchiseptica strain 110H and 110NH
harboring pBBRP9GFP to Vero cells. The values on y- axis indicate mean fluorescence
intensity as measured by flow cytometry analysis of Vero cell suspensions treated with
bacteria. Untreated Vero cells similarly incubated were used as negative controls
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Figure 6
Comparison of growth curves for wild type and recombinant B. bronchiseptica.
Overnight cultures of B. bronchiseptica 110H with pBBRP9GFP and pBBRGFP were
inocula ted into LB broth containing kanamycin. Wild-type 110H was similarly
inoculated into LB broth without kanamycin. At designated time points A590 was
measured and recorded.

101

110H
110HGFP
110HP9GFP

1.2
1

OD590

0.8
0.6
0.4
0.2
0
0

5

10

15

20

25

30

35

HOURS

102

Figure 7
In vivo GFP expression in B. bronchiseptica. (A) Bright field image of 8µm cryosection
of trachea of mouse 3 hours post inoculation with B. bronchiseptica 110H harboring
pBBRP9GFP. (B) Corresponding confocal scanning image of section seen in A with GFP
expressing bacteria attached to the ciliated epithelium. Magnification X630
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PART 3
Mouse inoculation studies, Immunization of mice with
recombinant Bordetella bronchiseptica expressing Pasteurella
multocida toxin fragment or green fluorescent protein
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Abstract
Bordetella bronchiseptica colonizes ciliated epithelium of the upper respiratory tract
of a wide variety of mammals. The role of Bordetella bronchiseptica and
Pasteurella multocida toxin in the disease, atrophic rhinitis, of pigs is well documented.
In this study, a non-toxic, protective P. multocida toxin fragment (PMTCE) and green
fluorescent protein (GFP) were expressed in B. bronchiseptica from genes cloned into a
broad-host-range plasmid vector, PBBR1MCS2, and placed under the control of a
promoter region isolated from B. bronchiseptica that appears to be a member of the heat
shock protein gene family. While wild-type and recombinant B. bronchiseptica colonized
the mouse respiratory tract effectively, the plasmid was no longer detected from the
organism after 72 hours post- inoculation. After a single intranasal inoculation, IgM, IgA
and IgG responses to B. bronchiseptica were detected in serum and broncheoalveolar
lavage samples. PMTCE specific antibodies were not detected. Four intranasal
inoculations with B. bronchiseptica expressing green fluorescent protein induced
systemic and mucosal immune responses to GFP; however, similar inoculations with B.
bronchiseptica expressing the PMTCE fragment did not induce detectable PMTCE
specific immune responses.
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Introduction
Atrophic rhinitis (AR) is an upper respiratory tract disease of pigs characterized by
degeneration and atrophy of nasal turbinate bones leading to visible distortion and
shortening of the snout [9, 28]. This disease is of major economic importance to pig
breeders all over the world. Bacterial etiologies identified in this condition are toxigenic
strains of Pasteurella multocida and virulent strains of Bordetella bronchiseptica, alone,
or combined with environmental factors like dust, ammonia and other physical or
chemical irritants [2, 6, 10, 26, 29]. Pasteurella multocida is an important veterinary
pathogen involved in diseases such as atrophic rhinitis in swine, fowl cholera in birds,
hemorrhagic septicemia in cattle and other respiratory diseases in lab animals [2]. Many
capsular type D and occasional type A strains of P. multocida produce a potent,
intracellular, heat- labile, 146Kd, mitogenic toxin (PMT), which is a major virulence
factor in atrophic rhinitis [5, 6, 11]. The role played by P. multocida and B.
bronchiseptica in AR is documented in a number of experimental studies [3, 4, 19, 27].
B. bronchiseptica, is widely distributed in swine herds with and without atrophic rhinitis.
The infection with B. bronchiseptica can lead to mild non-progressive forms of atrophic
rhinitis that do not affect growth rate [6]. Toxigenic type D P. multocida is the most
common isolate in severe, progressive, growth retarding atrophic rhinitis [6].
Experimental inoculation of pigs with cell- free extracts of P. multocida or purified toxin
can also lead to severe, progressive atrophic rhinitis [11]. Experimental infections in
gnotobiotic pigs implicate that colonization with virulent strains of B. bronchiseptica
damages the nasal mucosa and predisposes animals to colonization by toxigenic P.
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multocida [3, 4]. By itself, P. multocida does not readily colonize the nasal mucosa.
Vaccination and good management practices are the main approaches used to control this
condition [6]
Considering the proposed synergistic role of B. bronchiseptica and P. multocida in
AR, and the common usage of live-attenuated B. bronchiseptica vaccines and P.
multocida toxoid/ bacterins to control AR, further refinements of combined vaccines are
warranted. In this study, a non-toxic protective fragment of PMT and green fluorescent
protein (GFP) were expressed in B. bronchiseptica. Colonization kinetics, plasmid
stability and immune responses generated to B. bronchiseptica, PMT, and GFP were
evaluated in mice.
Materials and methods
Plasmids, bacterial strains, and enzymes
Origin of the B. bronchiseptica strains used in this study has been previously
described [1]. Strain 55 is a live attenuated B. bronchiseptica (ATCC 31437) vaccine
strain. Luria Bertani (LB) agar or broth with appropriate antibiotic selection at 37o C were
the conditions employed to grow all bacteria unless otherwise indicated. Smith
Baskerville medium was used for isolation of B. bronchiseptica from mouse respiratory
tract samples [23]. Restriction enzymes and LA Taq polymerase were products of
PANVERA, Madison WI. Wizard plus SV miniprep kit (Promega, Madison WI) was
used for plasmid isolation. The plasmid, pBBR1MCS2, (kindly provided by Kovach, M.
E) [12] was used for cloning and expression of the GFP gene and the PMT gene
fragment. A promoter region (P9) with homology to heat shock gene promoter region of
B. pertussis was isolated from B. bronchiseptica using a green fluorescent protein
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reporter system. This promoter was previously used to drive high- level expression of
GFP in four different strains of B. bronchiseptica [S. Rajeev, Dissertation, Part 2]. The
PMT gene fragment (PMTCE) consisted of base pairs 1999-4055 encoding the Cterminal 685 amino acids of PMT. This fragment was amplified from genomic DNA of
P. multocida (NCTC 12178) using LA Taq polymerase and primers 5'CGGGATCCCGTTATTGGAAAGCCTATTGGA-3' (forward) and 5'GGGGATCCGTTATAGTGCTCTTGTTAAGCG-3'(reverse). The PMTCE fragment
was cloned into BamHI digested and calf intestinal alkaline phosphatase treated
pBBRP9. The ligation mixture was transformed into E. coli and transformants were
selected on LB plates containing kanamycin (100µg/ml). The correct insertion of the
sequence was verified by restriction digestion with enzymes that cut within the PMTCE
fragment. Expression of PMTCE was detected on western blots of whole cell lysates
using PMT specific monoclonal antibody, Mab CRL1965, obtained from ATCC [13].
The resulting plasmid construct with PMTCE- promoter fusion was electroporated into B.
bronchiseptica strains 110H, 110NH, R5, strain 55 using a CELL-PORATOR
Electroporation system (GIBCO-BRL, Gaithersburg, MD) following manufacturer's
instructions. Electroporants were selected on kanamycin plates and tested for the
expression of PMTCE by Western blotting.
SDS-PAGE and Western blots
SDS-PAGE was performed using 10 % polyacrylamide gels (Ready Gels, Bio-Rad,
Hercules, CA) according to standard procedures. An overnight culture of each
B.bronchiseptica strain containing the recombinant plasmid, PBBRP9PMTCE, was
adjusted to an optical density (A590 ) of 0.5. One hundred µl of this suspension was
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centrifuged at 5000 rpm for one minute. The pellet was suspended in 100µl of 1x sample
buffer (Sigma Chemical Company, St. Louis, MO) and boiled for 10 minutes. Aliquots of
5µl were loaded to 10% polyacrylamide gels. The gels were electrotransferred to
nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk
solution in phosphate buffered saline with 0.05%Tween 20(PBS-T) for 30 minutes and
then reacted with a 1µg/ ml solution PMT specific monoclonal antibody, CRL 1965, in
1% nonfat dry milk in PBS-T for one hour. The membranes were washed four times in
PBST for 30 minutes and incubated with 1/10,000 dilution of peroxidase-conjugated antimouse IgG (Sigma Chemical Company). After washing four times in PBS-T for 30
minutes, the membranes were developed with chemiluminescent substrate
(SuperSignal R West Pico Substrate Pierce, Rockford, IL) and the membranes were
exposed to CL-XposureTM Film (Pierce, Rockford, IL) following the manufacturer's
guidelines.
Intranasal inoculation of mice
Four to six week-old female BALB/c mice were obtained from Harlan Laboratories
(Indianapolis, IN) and maintained by routine procedures in an AALAC accredited animal
facility. Groups of 3-4 mice were inoculated with ~ 1x10 5 CFU of either wild-type B.
bronchiseptica 110H or recombinant B. bronchiseptica 110H harboring pBBRP9PMTCE
or pBBRP9GFP. Mice were anaesthetized by Isoflurane (Abbott Laboratories, North
Chicago, IL) and 50µl of the inoculum was instilled into the nostrils. Mice were also
similarly immunized with B. bronchiseptica expressing GFP from the same promoter. In
a second experiment, mice, inoculated once by the intranasal route with 1x10 5 CFU were
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boosted three times at biweekly intervals via the intranasal route with 1x107 CFU of each
respective strain of B. bronchiseptica expressing GFP or PMTCE. An additional group of
mice primed with B. bronchiseptica expressing GFP were given a single intranasal
inoculation with 50 µg of purified recombinant GFP in PBS.
Colonization kinetics and in vivo plasmid stability
Mice were sacrificed at designated time points and the entire lungs and trachea
were collected aseptically. The tissue was homogenized and serial dilutions were plated
onto Smith Baskerville media with and without kanamycin. The plates were incubated for
48 hours at 37 o C and colony counts were performed. The percentage of kanamycin
resistant B. bronchiseptica colonies compared to the total number of colonies recovered
on non-selective media was calculated. The colonization studies were continued until the
colony counts reached minimum detectable levels (56 days).
Antibody response
Mice were bled from the retro-orbital sinus on 14, 28, 42 and 56 days postinoculation. Nasal and broncheoalveolar lavage (NBAL) were collected at the same time
points using a 24-gauge teflon catheter by flushing the lung, trachea and nasal cavity with
2 ml of PBS. Pooled samples were centrifuged at 3000 rpm to remove particulate matter.
Lavage samples and sera were stored at -70o C until further evaluation. Lavage samples
that were visibly contaminated with blood were discarded.
A kinetic enzyme linked immunosorbent assay (KELISA) was performed to evaluate
the antibody response to B. bronchiseptica and PMTCE. In brief, 96-well plates
(Immulon 2HB, Dynex) were coated overnight either with a suspension of B.
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bronchiseptica (strain 110H grown on TSA and adjusted to optical density, A590, of 0.1
in PBS), purified recombinant PMTCE (10µg/ ml in PBS) or purified recombinant GFP
(10 µg/ml). Plates were washed four times in PBS-T and blocked for 30 minutes with
PBS-T. One hundred µl of serum (1/40 dilution) or undiluted NBAL was added to plates
and incubated for 2 hrs at 37o C. Plates were washed four times with PBS-T and incubated
with peroxidase-conjugated secondary antibodies, anti- mouse IgG (1/2000), IgM
(1/1000), and IgA (1/1000) in PBS-T. Plates were washed four times with PBS-T and
developed with 100µl of substrate solution, 2,2'-azino diethylbenzothiazoline-6-sulphonic
acid (ABTS, Sigma Chemical Company, St Louis MO) and hydrogen peroxide. The
plates were read kinetically at A405 using ELx800 ELISA reader (BIO-TEK instruments
Inc., Winooski, VT). The plates were read 7 times at one-minute intervals, the maximum
slope (KELISA slope is directly proportional to the amount of antibody bound) was
calculated using KCjunior software (BIO-TEK instruments Inc, Winooski, VT)
Statistical analyses
The significance of differences between groups was determined by Student’s t-tests.
The data are expressed as mean +/- standard error of mean. P values < 0.05 were
considered significant.
Results
Cloning and expression of PMTCE in B. bronchiseptica
Initial attempts to express a previous ly reported 125kD, non-toxic, N-terminal
deletion mutant of PMT [21, 22] were unsuccessful. The recombinant
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B. bronchiseptica harboring this plasmid exhibited marked reduction in growth in vitro
and did not show any expression of this protein on immunoblots. We have identified Nterminal and C-terminal recombinant PMT protein fragments which can protect mice
from lethal challenge with PMT [20]. Intraperitoneal immunization with these proteins in
Freund's incomplete adjuvant elicited high level of anti-PMT antibodies and protected
mice from intraperitoneal challenge with P. multocida toxin [20]. The C-terminal
protective fragment (PMTCE) was utilized for expression in B. bronchiseptica.
A schematic representation of the expression plasmid is given in Figure 1(appendix). A
PMT specific monoclonal antibody, CRL-1965, was used for detection of expression of
this protein in B. bronchiseptica [13]. PMTCE expression was initially detected in
electroporants of all strains of B. bronchiseptica and in E. coli. After storage at -70o C,
repropagation and examination, B. bronchiseptica strain 55 no longer produced a reactive
protein band on western blot. The expected protein band of 80kD (76kD PMTCE+ 4kD
from the promoter region) was seen on Western blot with chemiluminiscent substrate
(Figure 2). However, the bands were not visible in Western blots developed with
colorimetric substrate, indicating that the amount of protein produced was low. The
amount of protein in each band was quantitated on Western blots by un-SCAN-IT TM
(Silk Scientific Corporation). B. bronchiseptica strains 110H, 110NH, and R5 expressed
6.4µg/0.5OD/ml , 6.2µg/0.5OD/ml, and 74µg/0.5OD/ml, respectively. Each strain that
expressed PMTCE and affinity purified PMTCE had a second immunoreactive band that
is presumed to be a degradative fragment. Such fragments have been previously reported
in purified native and recombinant PMT [20]. A third non-specific band was observed in
all samples including the negative controls indicating possible cross reactivity of the
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monoclonal antibody with some component in B. bronchiseptica. Expression of PMTCE
in B. bronchiseptica did not affect the growth in vitro (Figure 3).
Plasmid stability and colonization kinetics
The proportion of plasmid bearing recombinant B. bronchiseptica in lungs and
trachea of mice was determined by comparing the number of B. bronchiseptica CFU
obtained on Smith Baskerville medium with kanamycin selection to the number of B.
bronchiseptica CFU obtained on Smith Baskerville without kanamycin selection. B.
bronchiseptica was not isolated from any of the uninfected mice. The percentage of
kanamycin resistant colonies recovered from mice is shown in figure 4. Forty five percent
of the colonies harbored recombinant plasmid at 1hr post- inoculation. This frequency
gradually decreased to 0.007% at 72 hours post- inoculation. Recombinant and wild type
B. bronchiseptica colonized the respiratory tract of mice (Figure 5). The number of
organisms recovered increased until 7 days post- inoculation and gradually decreased
thereafter. By day 56, the number of organisms recovered was close to the minimum
detectable levels. There was no significant difference (p<0.05) in the total number of
organisms recovered at any time point from mice inoculated with wild-type or
recombinant B. bronchiseptica. However, colonization of wild-type and recombinant
B. bronchiseptica can not be compared because of the rapid loss of the plasmid.
Antibody response in mice
Antibody responses generated against B. bronchiseptica and the heterologous
antigens, PMTCE and GFP after intranasal inoculation with live B. bronchiseptica were
evaluated by KELISA [15, 30, 31]. KELISA measures the rate of color development
during the initial period of reaction, and is represented by the maximum slope, which is
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directly, proportional to the amount of secondary antibody conjugate bound. KELISA
performed using a single serum dilution was reported to be as sensitive and specific as
determining the endpoint titer [30]. IgG, IgA and IgM levels were measured in individual
serum samples and pooled NBAL samples. A single intranasal inoculation with wild-type
and recombinant B. bronchiseptica induced marked B. bronchiseptica specific antibodies
in the serum and NBAL (Figure 6)
B. bronchiseptica-specific serum IgM levels were detected at 14 day post
inoculation and remained stable throughout the period analyzed. Serum IgG levels
increased gradually in wild-type and recombinant B. bronchiseptica inoculated mice. The
serum IgG, levels to B. bronchiseptica were significantly higher (p= >0.05) in groups
inoculated with wild-type organisms compared to B. bronchiseptica expressing PMTCE.
An increase in B. bronchiseptica specific serum IgA levels was also detected in the
serum. In the NBAL an initial increase in IgM levels were followed by stable levels.
B. bronchiseptica specific IgG and IgA were also observed in NBAL. The PBS
inoculated controls did not produce any antibody response to B. bronchiseptica.
A single intranasal inoculation with recombinant B. bronchiseptica either expressing
GFP or PMTCE did not induce detectable antibody responses to the respective proteins.
In a second experiment, mice were first inoculated with 1x105 CFU of B. bronchiseptica
virulent strain, 110H or avirulent strain, 110NH expressing GFP or PMTCE by the
intranasal route followed by three intranasal booster inoculations with 1x107 organism at
14 day intervals.
After initial inoculation, 110H (Bvg+) infected mice became sick (characterized by
raised hairs and lethargy) and recovered by third day. However, mice inoculated with
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110NH (Bvg -) were normal. Even though inoculation with 1x105 B. bronchiseptica
110H produced transient illness in mice, mice initially inoculated with 1x105 B.
bronchiseptica 110H did not suffer any ill effects following intranasal exposure to 1x108
organisms 14 days later. Mice that had not received the initial exposure to 1x105
organisms died within 72 hours after intranasal exposure to 1x107 CFU of B.
bronchiseptica strain 110H. Multiple inoculations with higher number of organisms were
done to provide increased exposure to the heterologous antigens.
A PMT-specific immune response was not observed after exposure to the increased
number of organisms. However, a GFP-specific antibodies were obtained in NBAL and
serum after boosting with the increased dose of B. bronchiseptica 110H expressing GFP
(Figure 7). Serum GFP antibodies were predominantly of IgG subclass and NBAL GFP
antibodies were a mixture of IgA and IgG. Mice inoculated with avirulent 110NH and
boosted similarly did not produce detectable serum antibodies to GFP. There was a slight
increase in GFP-specific IgA in NBAL. When mice inoculated with recombinant B.
bronchiseptica strain 110H expressing GFP were boosted with 50µg of purified
recombinant GFP, high levels of GFP antibodies were observed in serum (Figure 8).
GFP-specific response was predominantly IgG. A similar increase in GFP-specific
response was not noticed in NBAL.
Discussion
Atrophic rhinitis is a disease of significant economic importance to US agriculture.
Vaccines against atrophic rhinitis consist of killed or live preparations of B.
bronchiseptica along with P. multocida bacterins or toxoid. Development of a safe and
bivalent live vaccine with avirulent B. bronchiseptica that expresses protective epitopes
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of PMT would represent a novel approach to control this disease. This is the first study to
demonstrate expression of a foreign protective antigen in B. bronchiseptica and the utility
of B. bronchiseptica as a mucosal vaccine vector directed to the respiratory tract.
A single intranasal inoculation with recombinant and wild-type B. bronchiseptica
induced both systemic and mucosal immune responses to B. bronchiseptica. While IgG
was the predominant antibody in the serum, IgA predominated in NBAL. In a recent
report, mucosal IgA antibodies against B. bronchiseptica were observed after intranasal
inoculation of mice with B. bronchiseptica and authors of this paper hypothesized that
this lack of mucosal IgA response was due to the toxins secreted by the type III secretion
machinery [14]
Plasmid instability leading to insufficient antigen exposure may have been the most
important factor responsible for our initial inability to detect an antibody response to
PMTCE and GFP after a single intranasal inoculation with recombinant B. bronchiseptica
expressing these proteins. It was hypothesized that booster inoculations with increased
numbers of organisms will provide increased exposure to the preformed fo reign antigens
contained in the inoculum. An antibody response was observed for GFP but not PMTCE.
The inability to detect antibodies to PMTCE compared to GFP after booster inoculations
might be attributed to the comparative low- level expression of PMTCE, plasmid
instability or antigenic differences of PMTCE expressed in B. bronchiseptica. The yield
of PMTCE in the E. coli expression system was also very low [20]. Therefore, production
and purification of large quantities of PMTCE is difficult and identifying stable
protective fragments of PMT for expression in B. bronchiseptica is worthwhile to pursue.
Recently, we have shown that the molecular chimerization of Fim N protein of
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B. bronchiseptica with an unstable protective fragment of leukotoxin of Mannheimia
haemolytica augmented neutralizing antibody response to leukotoxin [24]. Stabilization
of a PMT fragment by combining it with FIM N may also enhance the immune response
to PMT. An intranasal dose of 1x105 CFU could be given to mice without causing any
deleterious effects. Increasing the number of organisms in unprimed animal's lead to
100% mortality. We could inoculate with a 100 times greater dose of
B. bronchiseptica in previously exposed mice, without any deleterious effects. A
protective immune response in mice against B. bronchiseptica was probably generated as
early as 14 days. Four inoculations with B. bronchiseptica 110H expressing GFP induced
significantly greater GFP-specific antibody responses in the serum and NBAL than
110NH expressing GFP. B. bronchiseptica 110H is a Bvg+ strain which effectively
colonizes the respiratory tract where as Bvg- strains, like 110NH, do not have the
capability to colonize. The difference in immune responses to GFP in 110H and 110NH
infected mice suggests that, colonization played an important role in the generation of
immune response against GFP. In addition to simply influencing the level of antigen that
the immune system was exposed to, it is also possible, as previously suggested [14], that
adhesins and other virulence factors produced by B. bronchiseptica colonization may
have produced immunomodulating effects.
A second intranasal inoculation with recombinant GFP, after initial inoculation with
B. bronchiseptica 110H expressing GFP induced systemic GFP-specific antibodies;
whereas, control animals inoculated with GFP in PBS did not. This increase in response
indicates that there was a priming effect after inoculation with B. bronchiseptica 110H
expressing GFP, but not with 110NH that expressed GFP. Intranasal priming with
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recombinant B. pertussis and subsequent intranasal boosting with the foreign antigen
resulted in an effective systemic response against the foreign antigen [16]. Our
experiment gave similar results and suggests that this mode of immunization could be
utilized to generate systemic humoral immune responses against specific protective
antigens.
Virulent B. bronchiseptica is unsuitable for field vaccination purposes. The creation
of selected mutations in virulence genes like adenylate cyclase toxin and dermonecrotic
toxin, along with chromosomal integration of the genes encoding the foreign antigen may
be ideal. In B. pertussis, chromosomal integration was utilized for expression of a
heterologous antigen [17, 25]. Improving the stability of the plasmid vector by
construction of balanced lethal vectors as described in Salmonella [7] or by incorporating
a post-segregational killing function without manipulation of the live host can be done
[18]. While chromosomal integration may stabilize expression, it usually leads to low
level expression, which can result in sub-optimum immune responses. Stable multicopy
plasmid vectors can overcome this by the overexpression of antigen needed to generate
an effective immune response [8].
Identification of essential protective antigens and improved delivery of vaccine
components is essential for future vaccine development. Live-attenuated B.
bronchiseptica vaccines are widely accepted in animals and molecular methods to
genetically inactivate unwanted traits are available; therefore, construction of a live B.
bronchiseptica that expresses protective PMT antigens is desirable from the standpoint of
both safety and efficacy. Further manipulations of host strain, improvements in plasmid
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stability and stabilization of heterologous antigen expression are essential to make this
system effective.

120

References

121

1.

Burns Jr, EH, Norman JM, Hatcher MD, Bemis DA. Fimbriae and determination
of host species specificity of Bordetella bronchiseptica. J Clin Microbiol 1993;
3:1838-1844.

2.

Chanter N, Magyar T, Rutter JM. Interactions between Bordetella bronchiseptica
and toxigenic Pasteurella multocida in atrophic rhinitis of pigs. Res Vet Sci 1989;
7, 48-53.

3.

Daniel GM, Freese W, Henry S, Stevermer E, Straw B, Switzer WP. An up-to-date
review of atrophic rhinitis. Vet Med 1986;1:5-744.

4.

De Jong MF, Akkermans JPW M. Investigation into pathogenesis of atrophic
rhinitis I. Atrophic rhinitis caused by Bordetella bronchiseptica and Pasteurella
multocida and the meaning of a thermolabile toxin of P. multocida.
Vet Q 1986; 8: 204-214.

5.

Foged NT, Nielson JP, and Jorsal SE. Protection of pigs against progressive atrophic
rhinitis with Pasteurella multocida toxin purified by monoclonal antibodies.
Vet Rec 1989; 125: 7-11.

6.

Foged NT. The Pasteurella multocida toxin. The characterization of the toxin and its
significance in the diagnosis and prevention of progressive atrophic rhinitis in pigs.
APMIS Suppl 1992; 25: 1-56.

7.

Galen JE, Nair J, Wang JY, Wasserman SS, Tanner MK, Sztein MB, Levine MM.
Optimization of plasmid maintenance in the attenuated live vector vaccine strain
Salmonella typhi CVD908-htrA. Infect Immun 1999; 67: 6424-6433.

122

8.

Galen JE, Levine MM. Can a flawless live vector vaccine be engineered? Trends
Microbiol 2001; 9: 372-375.

9.

Goodnow R.A. Biology of Bordetella bronchiseptica. Microbiol
Rev 1980;44, 722-738.

10.

Hamilton TD, Roe JM, Webster AJF. Synergistic role of gaseous ammonia in
etiology of Pasteurella multocida- induced atrophic rhinitis in swine. J Clin
Microbiol 1996;34; 2185-2190.

11.

Kamp EM, Kimman TG. Induction of nasal turbinate atrophy in germ- free pigs,
using Pasteurella multocida as well as bacteria free crude extract and purified
dermonecrotic toxin of P. multocida. Am J Vet Res 1988; 49;1844-1849.

12.

Kovach ME, Elzer PH, Hill DS, Robertson GT, Farris MA, Roop II RM, Peterson
KM. Four new derivatives of the broad- host-range cloning vector pBBR1MCS,
carrying different antibiotic-resistance cassettes. Gene 1995;166:175-176.

13.

Magyar T, Rimler RB. Detection and enume ration of toxin producing Pasteurella
multocida with a colony blot assay. J Clin Micro 1991; 29: 1328-1332.

14.

Mattoo S, Miller JF, Cotter PA. Role of Bordetella bronchiseptica fimbriae in
tracheal colonization and development of a humoral immune response. Infect
Immun 2000;68: 2024-33.

15.

McDonough PL, Jocobson RH, Timoney JF, Mutalib A, Kradel DC, Chang YF,
Shin SJ, Lein DH, Trock, S, Wheeler K. Interpretations of antibody responses to
Salmonella enterica serotype enteritidis gm flagellin in poultry flocks are
enhanced by a kinetic-based enzyme linked immunosorbent assay.
Clin Diag Lab Immunol 1998; 5: 550-555.
123

16.

Mielcarek N, Cornette J, Schacht AM, Pierce RJR, Locht C, Capron A, Riveau G.
Intranasal priming with recombinant B. pertussis for the induction of a systemic
immune response against a heterologous antigen. Infect Immun 1997;65: 544-550.

17.

Mielcarek N, Nordstorm I, Menozzi FD, Locht C, Homgren J. Genital antibody
responses in mice after intranasal infection with an attenuated
candidate vector strain of Bordetella pertussis. Infect Immun 2000;68: 485-491.

18.

Nakayama K, Kelley SM, Curtiss III R. Construction of an Asd+ expression
cloning vector: stable maintenance and high level expression of cloned genes in a
salmonella vaccine strain. Bio/technology 1988; 6: 693-697.

19.

Nagano H, Nakai T, Horiguchi Y, Kume K. Isolation and characterization of
mutant strains of Bordetella bronchiseptica lacking dermonecrotic toxin producing
ability. J Clin Microbiol 1988; 26; 19830-19837.

20.

Nair RV. Construction of recombinant Pasteurella multocida toxin fragments and
evaluation of their immunogenicity and protective efficacy in mice. Thesis 2000.
University of Tennessee.

21.

Nielsen JP, Foged NT, Sorensen V, Bradford K, Bording A, Peterson SK.
Vaccination against progressive atrophic rhinitis with a recombinant Pasteurella
multocida toxin derivative. Can J Vet Res 1991; 55: 128-138.

22.

Peterson SK, Foged NT, Bording A, Nielsen JP, Reimann HK, Frandsen PL.
Recombinant derrivatives of Pasteurella multocida toxin: candidates for vaccine
against atrophic rhinitis. Infect Immun 1991;57: 1387-1391.

124

23.

Quinn PJ. Bordetella species. pp 280-283In Clinical Veterinary Microbiology
1994 Wolfe, London.

24.

Rajeev S, Kania SA, Nair RV, McPherson JT, Moore RN, Bemis DA. Bordetella
bronchiseptica fimbrial protein-enhanced immunogenicity of a Mannheimia
haemolytica leukotoxin fragment. Vaccine 2001; 19:4842-4850.

25.

Renauld-Mongenie G, Meilcarek N, Cornette J, Schat AM, Capron A, Riveau G,
Locht C. Induction of mucosal immune responses against a heterologous antigen
fused to filamentous hemagglutinin after intranasal immunization with
recombinant Bordetella pertussis. Proc Natl Acad Sci 1996; 93:7944-7949.

26.

Rhodes MB, New CWJR, Baker PK, Hogg A, Underdahl NR. Bordetella
bronchiseptica and toxigenic Type D Pasteurella multocida as agents of severe
atrophic rhinitis of swine. Vet Micrbiol 1987; 13:179-187.

27.

Roop II RM, Veit HP, Sinsky RJ, Veit SP, Hewlett EL, Kornegay HT. Virulence
factors of Bordetella bronchiseptica associated with the production of infectious
atrophic rhinitis in experimentally infected neonatal swine. Infect Immun 1987;
55,217-222.

28.

Rutter JM. Atrophic rhinitis in swine. Adv Vet Sci Comp Med 1985; 29:239-279.

29.

Rutter JM, Rojas X. Atrophic Rhinitis in gnotobiotic piglets: differences in the
pathogenicity of Pasteurella multocida in combined infections with Bordetella
bronchiseptica. Vet Rec 1982;49: 1844-1849.

30.

Snyder NH, Banks S, Murphy BR. Determination of antibody response to influenza
virus surface glycoproteins by Kinetic Enzyme linked Immunosorbent assay. J
Clin Microbiol 1988;26:2034-2040.

125

31.

Victor CW, Wilson BC, Peralta JM. Quantitative, single-tube kinetic-dependent
enzyme- linked immunosorbent assay (k-ELISA). Methods Enzymol
1983; 92:391-403.

126

Appendix

127

Figure 1
Schematic representation of recombinant plasmid vector pBBR1MCS2 expressing
P. multocida toxin fragment (PMTCE). Restriction sites used to clone in the fragment are
indicated. P9 is a constitutive promoter cloned upstream to PMTCE in frame to drive the
expression of the PMTCE.
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Figure 2
Expression of PMTCE in B. bronchiseptica.
Whole cells harboring the recombinant plasmid were subjected to SDS PAGE on a
10%polyacrylamide gel and electro- transferred to nitrocellulose membrane. Membranes
were probed with PMT specific monoclonal antibody, CRL-1965 and developed with
chemiluminescent substrate. Numbers on the left indicate the approximate positions of
prestained molecular weight markers in kilo Daltons. Lanes 1,3, 5, and 7 are lysates of
B. bronchiseptica strains 110H, 110NH, R5, and 55 harboring pBBRP9 without PMTCE
insert respectively. Lanes 2, 4, 6, and 8 contains lysates of B. bronchiseptica strains
110H, 110NH, R5, and 55 harboring pBBRP9PMTCE. Lane 9 contains 50ng of affinitypurified recombinant PMTCE.
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Figure 3
Comparison of growth curves
Overnight cultures of the recombinant B. bronchiseptica strain 110H harboring pBBRP9
and pBBRP9PMTCE were inoculated into LB broth containing kanamycin. Wild-type
B. bronchiseptica was also similarly inoculated into LB broth without kanamycin.
At designated time points optical densities at A590 were measured and recorded.
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Figure 4
In vivo stability of the recombinant plasmid in B. bronchiseptica.
Mice were inoculated with 1x105 B. bronchiseptica in PBS via the intranasal route. At
designated time points lungs and trachea were aseptically collected and homogenized,
serial dilutions were plated on to Smith Baskerville media with and without kanamycin.
The percentage of kanamycin resistant colonies in relation to the total number of colonies
recovered is reported.
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Figure 5
Colonization kinetics of B. bronchiseptica in mice.
Mice were inoculated with 1x105 B. bronchiseptica in PBS via the intranasal route. At
designated time points lungs and trachea were aseptically collected and homogenized,
serial dilutions were plated on to Smith Baskerville media. Total CFU recovered at
designated time points is reported.
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Figure 6
Antibody response to B. bronchiseptica in mice.
Mice were inoculated via the intranasal route with a suspension in PBS containing 1x105
wild-type or recombinant B. bronchiseptica110H expressing PMTCE. NBAL and serum
were collected at designated time points. IgG, IgM, and IgA responses were measured by
KELISA and reported as KELISA slope. The day at which the samples were collected is
given on x-axis. The control animals were inoculated with PBS
(A) Serum antibody response to B. bronchiseptica strain 110H in mice inoculated
with recombinant 110H expressing PMTCE.
(B) Serum antibody response to B. bronchiseptica strain 110H in mice inoculated
with wild-type.
(C) Mucosal antibody response to B. bronchiseptica strain 110H in mice inoculated
with recombinant 110H expressing PMTCE.
(D) Mucosal antibody response to B. bronchiseptica strain 110H in mice inoculated
with wild-type.
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Figure 7
Antibody response to GFP
Mice were inoculated with 1x105 recombinant B. bronchiseptica 110H expressing GFP,
110NH expressing GFP, 110H expressing PMTCE or PBS via the intranasal route. The
mice were boosted with 1x107 organisms three times at 14 day intervals. NBAL and
serum was collected on the 9th day after final boosting. GFP specific IgG, IgM, and IgA
response was measured by KELISA and reported as KELISA slope. (A) Serum antibody
response. (B) Mucosal antibody response
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Figure 8
Antibody response to GFP after boosting with recombinant GFP
Mice were inoculated with 1x105 recombinant B. bronchiseptica 110H, recombinant
110NH expressing GFP, wild-type 110H, wild-type 110NH or PBS via the intranasal
route. On the 14th day post- inoculation the mice were given 50µg of GFP in PBS via the
intranasal route. NBAL and serum were collected on the 9th day after inoculation with
GFP. GFP-specific IgG, IgM, and IgA antibodies were measured by KELISA and
reported as KELISA slope. A) Serum antibody response. B) Mucosal antibody response
X-axis labels, 1-strain 110H followed by GFP, 2-110NH followed by GFP, 3- 110H
expressing GFP followed by GFP, 4-110NH expressing GFP followed by GFP, 5- PBS
followed by GFP, 6- PBS alone.
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PART 4

Bordetella bronchiseptica fimbrial protein-enhanced
immunogenicity of a Mannheimia haemolytica
leukotoxin fragment
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Abstract
Leukotoxin produced by Mannheimia (Pasteurella) haemolytica is an important
virulence factor in shipping fever pneumonia in feedlot cattle and is a critical protective
antigen. In this study, the immune response to a chimeric protein generated by combining
a gene fragment encoding neutralizing epitopes of M. haemolytica leukotoxin and a
fimbrial protein gene (fim N) from Bordetella bronchiseptica was evaluated. The
recombinant gene was cloned in a bacterial expression vector under the control of the tac
promoter and expressed as a fusion protein with glutathione-S-transferase (GST) in
Escherichia coli. Immunization of mice with the recombinant protein, GST-LTXFIM
elicited a significantly stronger anti- leukotoxin antibody response than comparable
immunizations with GST-LTX fusion proteins lacking FIM N. The GST-LTXFIM was
also more stable than GST-LTX during storage at -80o C, thus alleviating a stability
problem inherent to leukotoxin. This chimeric protein may be a candidate for inclusion in
new generation vaccines against shipping fever pneumonia.
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Introduction
Shipping fever pneumonia in feedlot cattle is a multifactorial disease that results in
great economic loss in the United States cattle industry. Mannheimia (Pasteurella)
haemolytica is the primary bacterium associated with this condition. Leukotoxin secreted
by M. haemolytica is a ruminant leukocyte-specific, pore- forming cytotoxin of the RTX
(repeat in toxin) family of toxins, and is an important virulence factor of this orga nism (3,
6, 8, 29, 31). Protection of cattle from shipping fever pneumonia has been correlated with
the presence of leukotoxin- neutralizing antibodies (19, 20, 21, 25, 26, 27, 28). However,
leukotoxin- neutralizing antibody responses induced by current vaccines are highly
variable, and this disease remains an important health problem in feedlot cattle (28).
Instability of native leukotoxin has led to difficulty in its purification and limited the
inclusion of this antigen in vaccine preparations (7). The toxicity of native, biologically
active leukotoxin may also be a concern for vaccine safety.
The gene encoding leukotoxin has been fully sequenced (12) and a number of
leukotoxin- neutralizing monoclonal antibodies against linear and conformational
epitopes have been mapped to peptides derived from the carboxy-terminal region of
leukotoxin (10, 16). A minimal leukotoxin A gene fragment encoding carboxy-terminal
aminoacids 713-939 was previously characterized and the truncated non-cytolytic
recombinant protein (LTX) was recognized by three leukotoxin- neutralizing monoclonal
antibodies (18). Immunization with this recombinant protein in Freund’s complete
adjuvant (CFA) elicited considerable leukotoxin neutralizing-antibody response in
rabbits; however, the protein was unstable on storage at -80 o C (18).
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Fimbriae are important virulence factors involved in attachment of many Gramnegative bacteria to host tissues (15). Fimbrial antigens are highly immunogenic and
generally abundant on bacterial surfaces. We recently cloned and characterized a novel
fimbrial gene, fim N, from Bordetella bronchiseptica (14), an upper respiratory tract
pathogen that affects a wide variety of host animals (4, 11). Adhesins that serve
colonizing functions in Bordetella spp. may be useful in delivering heterologous antigens
and several B. pertussis antigens, including pertussis toxin (1, 2), adenylate cyclase toxin
(23), tracheal colonization factor (5) and filamentous haemagglutinin (22) have been
expressed as heterologous recombinant proteins. Fimbrial protein from Escherichia coli
has been documented as effective carriers of heterologous antigens (15). In the course of
studying the suitability of FIM N as a heterologous antigen carrier, we observed that a
LTX-FIM N recomb inant fusion protein enhanced the immunogenicity of LTX beyond
that which had been observed with other LTX recombinant proteins. This report
describes the construction and immunologic evaluation of a LTX-FIM N recombinant
fusion protein.
Materials and methods
Plasmids, bacterial strains, chemicals and enzymes
Plasmids used in this study are described in Table 1. Escherichia coli strains,
Top10F’ (Invitrogen Inc., San Diego, CA) and BL21-Gold (Stratagene, La Jolla, CA)
were used for cloning and protein expression, respectively. Restriction enzymes were
products of Gibco/BRL (Gaithersburg, MD) and New England Biolabs (Beverly, MA).
Taq polymerase was obtained from PANVERA Corporation (Madison WI). DNAse, 3[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), and isopropyl β-D148

thiogalactopyranoside (IPTG) were purchased from Sigma Chemical Company (St.
Louis, MO).
Construction of expression plasmids
Polymerase Chain Reaction (PCR) was performed in a Gene Amp PCR system 9600
(Perkin Elmer, Narcross, GA). The fim N gene (without putative signal sequence) was
amplified from PCR2-FIM by PCR using primers ECOFWD (5’GGGAATTC ACGATCGTGATCACCGGCA -3’) and XHOREV (5’GGCTCGAGGATTATCCTTATCAAGCC -3’) with engineered restriction sites
(underlined). The product was digested with XhoI and EcoRI, gel purified (Gel
Extraction kit, Quiagen, Valencia, CA) and cloned into pGEX-5X-1 that had been predigested with XhoI and EcoRI. The resulting plasmid was named pGEX-FIM. A 663 bp
fragment of M. haemolytica leukotoxin A gene, encoding amino acids 719- 939, was
amplified from pGEX-LT FUSION by PCR with primers LTBAMF (5’GGGGATCCATAACGATATCTTTAAAGG-3’) and LTECOR (5’GGGAATTCCATTGAAGTTGGAGCCAC-3’). Engineered BamHI and EcoRI
restriction sites are underlined. The PCR product was cloned into BamHI and EcoRI sites
of pGEX-5X-1 to form plasmid pGEX-LTBE. To construct the plasmid pGEX-LTFIM,
the EcoRI and XhoI digested fimN fragment from pGEX-FIM was ligated to the EcoRI
and XhoI sites of pGEX-LTBE. The GST gene was amplified from pGEX-5X-1 vector
using primers 5’-TATTGGAAAATTAAGGGCCTCGAGCAA -3’and 5’TATATACTCGAGGGATTTCAAGTACTT -3’, and cloned into the XhoI site of pGEXLT FUSION downstream to leukotoxin fragment. This plasmid was called pGEXLTGST. The 5’ and 3’ ends of all constructs were sequenced at the University of
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Tennessee DNA sequencing facility on an Applied Biosystems 373 automated sequencer.
All recombinant plasmids were introduced into E.coli BL21-Gold by transformation (16).
Expression and purification of the recombinant proteins
E. coli BL21-Gold cells harboring the expression plasmids were inoculated into one
liter of LB broth containing ampicillin (100 µg/ml) and incubated at 37o C, with rotary
shaking (220 rpm), to an optical density (A600 ) of 0.6-0.8. Plasmid gene expression was
induced with IPTG (final concentration, 0.2 mM) and after two hours of further
incubation, bacteria were harvested by centrifugation at 5000 x g for 10 minutes. The
pellet was used immediately for protein purification or stored at -80o C until further use.
GST-LTX was initially purified under non-denaturing conditions according to the
manufacturer’s (GST Gene Fusion System, Pharmacia, Piscataway, NJ) protocol.
Subsequent purification of this protein and all other recomb inant proteins was performed
by a modification of the procedure reported by Frangioni and Neil (9). Briefly, cells were
suspended in 100ml of STE buffer (10 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1 mM
EDTA) with 100 µg /ml of lysozyme. Dithiotreitol (DTT) was added to a final
concentration of 5 mM, and the cell suspension was incubated on ice for 30 minutes.
SarkosylTM (N-lauroylsarcosine) was added to a final concentration of 1.5%, and the
suspension was sonicated for one minute to reduce the viscosity. DNAase (1200U) and
Triton X-100 (final concentration 1%) were added, and the mixture was incubated on ice
with intermittent shaking for one hour. After centrifugation (14,000 x g for 20 minutes),
the supernatant was mixed with a one ml slurry of 50% GST sepharose (Pharmacia,
Piscataway, NJ) and incubated at room temperature with gentle shaking for 4 h. The GST
sepharose was washed four times with PBS (phosphate buffered saline), and bound
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proteins were eluted with 6 M guanidium chloride in PBS. The eluted fractio n was
dialyzed overnight in PBS. Protein concentrations were determined using the
Bicinchoninic Acid Assay (Sigma Chemical Company, St Louis, MO). Samples were
adjusted to contain 1 mg protein /ml in PBS and stored at -80o C until further use. The
preparations were examined by SDS-PAGE and immunoblotting with leukotoxin and
fimbriae specific antibodies.
Animals and Immunizations
Four-week old New Zealand White rabbits and 4-6 week old female BALB/c mice
(Harlan Laboratories, Indianapolis, IN) were maintained by routine procedures in an
AALAC accredited laboratory animal facility. Rabbits were inoculated with 500 µg of
recombinant protein (1mg/ml), GST-FIM, GST-LTX or GST-LTXFIM, emulsified in an
equal volume of Freund’s incomplete adjuvant (IFA). Intramuscular injections were
given to each rabbit on days 0, 14, 28, and 42, respectively. Blood was collected from
rabbits on days 0 and 51.
Groups of 5-7 mice were immunized with recombinant proteins by intraperitoneal
injection. Each animal received three 100 µl doses containing 50 µg of antigen. Antigens
used for the first injections were given with an equal volume of CFA, IFA or PBS.
Booster injections given on day 14, were in IFA or PBS, and final injections on day 35
were given in PBS. A control group received CFA + PBS as the first injection, followed
by IFA+PBS as second injection and PBS as third injection. Four groups of 5-7 mice
were inoculated with 25µg, 50µg, 75µg, or 100µg of GST-LTXFIM in IFA. Booster
injections were given as described above. All mice were bled from the retro-orbital sinus
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nine days after the final immunization. After serum separation, all samples were stored at
-80oC.
Evaluation of antibody response
A capture ELISA using mouse monoclonal antibody MAb Ltx35 (10) was performed
to determine anti- leukotoxin antibody titers in rabbits. In brief, 96-well plates (Immulon
2HB, Dynex Technologies Inc, Chantilly, VA) were coated with MAb Ltx35 in PBS
(10µg/ml), washed four times with PBS-0.05% Tween 20 (PBS-T) and blocked for 30
minutes at 37o C in PBS-T. Native leukotoxin was prepared from culture supernatant of
M. haemolytica as previously described (24), and was added to the wells at a previously
determined optimum dilution of 1:100 and incubated for one hour at 37o C. After washing
four times with PBS-T, plates were incubated for 2 h at 37o C with two-fold serial
dilutions of serum from immunized animals. All serum dilutions were made in PBS-T.
Plates were washed four times in PBS-T, incubated with secondary antibody (peroxidase
conjugated goat anti- Rabbit IgG) for 1 h and developed by adding 100 µl of substrate
solution containing 2,2’-azino di-ethylbenzothiazoline-6-sulfonic acid (ABTS, Sigma
Chemical Company, St Louis, MO) and hydrogen peroxide. The A405 was measured in an
EIA reader (BIO-TEK Instruments, Winooski, VT). The titers were determined as the
reciprocal of the highest dilution of serum that gave an absorbance reading three times
the conjugate control. For measuring antibodies in mice, leukotoxin was captured with
ammonium sulfate precipitated rabbit polyclonal anti- leukotoxin serum (1/2000 dilution)
and peroxidase conjugated rabbit anti- mouse IgG was used as the secondary antibody.
Anti-FIM N antibodies were measured by ELISA as previously described (14).
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Leukotoxin Neutralization Assays
Leukotoxin neutralization activity of serum was analyzed by a colorimetric
cytotoxicity assay using tetrazolium dye (MTT) and BL-3 cells as previous ly described
(27, 29). Initially, native leukotoxin, prepared from culture supernatant of M.
haemolytica was titrated using BL-3 cells to determine the toxin potency. One toxin unit
was defined as the dilution of leukotoxin that killed 50% of the target cells. Heat
inactivated (56o C for 30 minutes) serum samples diluted in RPMI-1640 were mixed with
15 units of leukotoxin (optimal concentration was determined by titration) for 30 minutes
at 4o C in triplicate wells of a 96 well plate. BL-3 cells (6.25 x104 /well) were added to the
plates and incubated for 45 minutes at 37o C with 5% CO2 . MTT (10mg/ml in RPMI
1640) was added and incubated for 4 hours. The optical density (A562 ) was measured
after lysing the cells with acid alcohol (0.4N HCl in isopropanol). The percentage of
leukotoxin neutralization in each sample was calculated as described by Vega et al. (30)
by using the formula:
{1-[(OD of the serum treated cells - OD of leukotoxin plus serum treated cells) / (OD of
untreated cell control - OD of leukotoxin treated cells)]} x100. A cut-off value of 50%
neutralization was considered positive for end point determination. Neutralization titers
were determined for rabbit sera using two-fold serial dilutions. All mouse sera were
analyzed at single dilutions of 1:60, 1:200 and 1:600. Like dilutions from each individual
mouse were tested on a single day with same batch of cells and leukotoxin.
Statistical analyses
Statistical analyses were done using Statistical Analysis Software (SAS version 8) by
the General Linear Model (GLM) procedure. The significance of differences between
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groups for ELISA titers and leukotoxin neutralization activity was determined by
Student’s t-tests. The data are expressed as mean +/- standard error of mean. P values <
0.05 were considered significant.
Results
Plasmid construction, recombinant protein expression and purification
The plasmids, pGEX-LTBE, pGEX-LTFIM, pGEX-FIM and pGEX-LTGST, were
constructed in this study (Table 1, Appendix). Each plasmid encoded the GS T gene
downstream of a tac promoter and also had either a gene fragment (nucleotides 26733336) encoding the carboxy-terminal portion of leukotoxin A, the 534 bp fragment
(nucleotides 90-624) of the fim N gene, or both. Plasmid, pGEX- LTGST, had a second
copy of a truncated GST gene cloned downstream from the leukotoxin fragment. All the
genes were inserted in the correct reading frame as determined by DNA sequence
analysis.
Each of the plasmids expressed recombinant protein in E. coli BL21-Gold after IPTG
induction as determined by SDS PAGE and Western blots (Figure 1, Appendix). The
stained polyacrylamide gels of whole-cell lysates showed prominent bands corresponding
to the predicted molecular weights of the expected recombinant proteins (48.7 kD for
GST-FIM, 53.5 kD for GST-LTX, 73.2 kD for GST- LTXFIM and 74.5 kD for GSTLTXGST). Recombinant proteins, GST-LTX, GST-LTXFIM and GST-LTXGST, were
recognized in Western blots by leukotoxin- neutralizing monoclonal antibodies MAb
Ltx35, MAb Ltx4 and MAb Ltx2 (10). Monoclonal antibodies, BPA10, BPA5, and
BPH2, specific for serotypes 2 fimbrial monomers of B. pertussis (kindly provided by M
Brennan, FDA ), reacted in Western blots with GST-FIM and GST-LTXFIM
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The majority of GST-LTXFIM and GST-FIM proteins were isolated from insoluble
cell lysate fractions and required purification under denaturing condition. GST-LTX was
recovered from soluble cell lysate fractions and was initially purified in non-denaturing
conditions. However, all protein preparations used for immunization were purified under
denaturing conditions by the same procedure. Upon dialysis, GST-FIM and GSTLTXFIM formed precipitates; whereas, GST-LTX did not. Purified recombinant fusion
proteins migrated to their predicted molecular weights in SDS-PAGE gels (Fig 2). The
SDS-PAGE banding pattern of GST-LTXFIM was unchanged, showing no signs of
degradation after storage at -80o C for up to one year. On Western blots, the stored GSTLTXFIM retained its reactivity to MAb Ltx35; whereas, GST-LTX did not (Figure 3).
GST-LTX produced varying patterns of low molecular weight banding, suggestive of
protein degradation, in different preparations
Antibody responses in Rabbits
Groups of two or three rabbits were immunized with chimeric proteins, GS TLTXFIM, GST-LTX, and GST-FIM. Native leukotoxin and HTFIM were used as ELISA
antigens. HTFIM was used instead of the homologous antigen in ELISA to avoid
reactivity with anti- GST antibodies. Pre-immune sera had no detectable anti- leukotoxin
or anti- HTFIM antibodies. Rabbits (n=3) immunized with GST-LTXFIM had higher
average ELISA titers (70,300 +/- 17, 100) against native leukotoxin than rabbits (n=3)
immunized with GST-LTX (38,900 +/- 500). However, anti-HTFIM titers were lower in
rabbits immunized with GST-LTXFIM (4200 +/- 1000) than those of rabbits (n=2)
immunized with GST-FIM alone (23, 000 +/-1400). Rabbits immunized with GST-FIM
did not produce detectable antibodies reactive with native leukotoxin and rabbits
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immunized with GST-LTX did not produce detectable HTFIM reactive antibodies.
Leukotoxin neutralization titers in the BL-3 cytotoxicity assay were higher in rabbits
immunized with GST-LTXFIM (340+/-130) compared to those immunized with GSTLTX (120 +/-15). The differences observed in ELISA and leukotoxin neutralization titers
were not statistically analyzed due to the low sample size. Rather, the rabbit study
provided preliminary data for a mouse study performed with larger groups of animals.
Antibody response in mice
The immunogenicity of LTX fusion proteins and adjuvant combinations were further
evaluated in mice. The anti- leukotoxin IgG titers were determined for all individual mice
(Figure 4A). All groups immunized with GST-LTXFIM produced significantly higher
anti- leukotoxin antibody responses compared to groups similarly immunized with GSTLTX (p< 0.01). The anti- leukotoxin ELISA titers of control mice were < 20. The group
of mice immunized with GST-LTXFIM in CFA had the highest anti- leukotoxin ELISA
titers and was significantly different from all other groups (P<0.01). The anti- leukotoxin
ELISA titers of mice immunized with GST-LTXFIM in IFA was not significantly
different from those similarly immunized with same antigen that had been stored at -80o C
for six months (p>0.05). However, anti- leukotoxin ELISA titers of these two groups were
significantly higher than GST-LTX in CFA (p<0.05). Anti- leukotoxin ELISA titers were
significantly lower in groups immunized with GST-LTXGST in IFA than groups
immunized with GST-LTXFIM either in IFA (p< 0.01) or CFA (p<0.001). The mice
immunized with GST-LTX without adjuvant and stored GST-LTX had the lowest antileukotoxin ELISA titers.
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The percentage of leukotoxin activity neutralized by each individual serum sample at
a screening serum dilution of 1:60, 1:200 and 1:600 was determined. The mean
leukotoxin neutralization activity of serum from individual groups of mice and the
number of animals which had a neutralization activity greater than 50% are shown in
Figure 4B. All the groups immunized with GST-LTXFIM induced significantly higher
leukotoxin neutralization activity compared to groups similarly immunized with GSTLTX. At the 1:60 dilution, serum from 25 out of 27 mice immunized with GST-LTXFIM
had leukotoxin neutralization activity greater than 50%, whereas, only 11out of 27 mice
in GST-LTX groups had leukotoxin neutralization activity greater than 50%. Out of 27
mice immunized with GST-LTXFIM, 11 were positive for neutralization activity at a
serum dilution of 1:200 and six were positive at a serum dilution of 1:600 (data not
shown). By contrast, in mice immunized with GST-LTX, 3 out of 27 mice at 1:200 serum
dilution and none at 1:600 had leukotoxin neutralization activity greater than 50% (data
not shown). None of the control animals had leukotoxin neutralization activity greater
than 50%. Neutralization activity was statistically analyzed for each group at the 1:60
serum dilution. There was no significant difference in neutralization activity of sera from
mice immunized with freshly prepared GST-LTXFIM in CFA, IFA or PBS, and mice
immunized with GST-LTXFIM that had been stored at -80o C for 6 months (p>0.05).
Mice immunized with GST-LTX in CFA had the highest anti- leukotoxin antibody
response among the GST-LTX groups. There was no significant difference in leukotoxin
neutralization activity between groups immunized with GST-LTX in IFA, stored GSTLTX in IFA and the control groups given CFA +PBS (p>0.05). The GST-LTX /CFA
combination was the only GST-LTX preparation that was able to induce a leukotoxin157

neutralizing antibody response which was comparable to those produced by GSTLTXFIM antigens. Leukotoxin neutralization activities of sera from mice immunized
GST-LTXGST in IFA was also significantly lower than those of sera from mice
immunized with GST-LTXFIM in CFA (p<0.01), IFA (p< 0.05) and PBS (p<0.05).
However, leukotoxin-neutralizing activity of sera from mice immunized with GSTLTXGST was not significantly higher than from those immunized with GST-LTX in
CFA (p>0.8), IFA (p>0.05) or PBS (p>0.6). Strong correlation between anti- leukotoxin
ELISA titers and leukotoxin neutralization activity was observed in groups immunized
with GST-LTXFIM (r = 0.60818, P = 0 .0008, n=27) but not in groups immunized with
GST-LTX (r = 0.35196, P = 0.0718, n=27). Groups of mice immunized with 25µg, 50µg,
75µg and 100µg of GST-LTXFIM in IFA, did not have significant differences in antileukotoxin IgG titers or leukotoxin neutralization activity (Figure 5).
Discussion
Leukotoxin is a major virulence factor in M. haemolytica- induced pneumonia of
feedlot cattle (3, 6, 8, 29, 31). There is a significant correlation between high levels of
leukotoxin- neutralizing antibodies and a reduction in pneumonic lesion scores in
naturally and experimentally infected cattle (19, 20, 21, 25, 26, 27, 28). However, the
instability of leukotoxin and the resulting difficulty in its purification have limited its use
as an additive component in vaccines (7). This report demonstrates that immunization
with a fusion protein consisting of the carboxy-terminal peptide of leukotoxin and FIM N
induced high levels of leukotoxin- neutralizing antibodies in laboratory animals. Unlike
GST-LTX, the chimeric GST- LTXFIM antigen was stable on storage at -80o C and
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induced high levels of leukotoxin- neutralizing antibody even without the use of
adjuvants.
The leukotoxin neutralization assay is very sensitive; variations in leukotoxin potency
and the sensitivity of target cells can greatly influence the outcome of the assay. It has
been reported that the coefficient of variation of this assay, performed on separate days,
ranged from 0-36% (30). In this study, the effects of day to day variations were
minimized by testing the serum from each individual on a single day using a single vial
of leukotoxin and the same batch of BL-3 cells. End points were determined for serial
dilutions of rabbit sera. The minimal dilution at which each individual mouse sample
could be compared was 1:60 and the assay at this dilution was performed twice on two
different days. Leukotoxin neutralization activity was also determined at 1:200 and
1:600 serum dilutions. It was estimated that the leukotoxin neutralization titers of GSTLTXFIM immunized mice were between 60 and 600. These levels were consistent with
the titers seen in rabbits and were as high as reported leukotoxin neutralization titers in
cattle (26, 27, 30). In GST-LTX groups, more than half of the individual serum samples
may have titers less than 60.
Mice immunized with antigens containing GST-LTXFIM consistently produced
higher levels of anti- leukotoxin antibodies than mice similarly immunized with LTX
antigens lacking FIM N. Inclusion of CFA in the GST-LTXFIM antigen significantly
increased the leukotoxin antibody response as measured by ELISA with native
leukotoxin as antigen, but did not significantly affect leukotoxin- neutralizing antibody
response in the BL-3 cell cytotoxicity assay. Doses of GST-LTXFIM antigen ranging
from 25µg - 100µg produced equivalent leukotoxin- neutralizing antibody responses.
159

These observations suggest that stringent immunization protocols (eg. high dose, and
adjuvants) may not be required to elicit maximum leukotoxin-neutralizing antibody
responses when the chimeric GST-LTXFIM protein is used. It was previously observed
that a recombinant fusion of leukotoxin and interleukin-2 produced an enhanced
lymphocyte proliferation response but did not enhance anti- leukotoxin antibody
production (13).
It was observed that the LTX-FIM immunogen, regardless of the adjuvant used,
consistently induced higher levels of leukotoxin- neutralizing activity in all groups and
that serum samples from mice immunized with LTX-FIM immunogen neutralized at least
50% of the cytotoxicity of 15 units of leukotoxin at dilutions where other LTX
immunogens lacking FIM N lost this capacity. The active toxin concentration used was
intentionally chosen to be several fold higher than normally used (15 vs 1-3 units) to
eliminate variability in cytotoxicity. Possibly more significant, was a much closer
statistical correlation between anti- leukotoxin ELISA titers and leukotoxin neutralizing
activity in sera from LTX-FIM immunized mice than in the sera from mice immunized
with LTX lacking FIM. The strong suggestion is that the FIM fusion enhances production
of potentially protective (neutralizing) antibodies more so than fusions lacking FIM N. A
stable subunit fragment of leukotoxin, such as GST-LTXFIM might provide a basis for
an ELISA with greater specificity for protective, neutralizing antibodies and would be of
great aid to vaccine evaluation.
The mechanism of enhancement of anti- leukotoxin antibody production following
fusion of FIM N to the carboxy-terminus of GST-LTX is unknown but may simply
reflect protection of exposed LTX epitopes against degradation. In vitro and in vivo
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degradation or instability of neutralizing epitopes at the carboxy-terminus of GST-LTX
may explain the lower responses to GST-LTX antigen preparations. This hypothesis is
supported by the observation that GST-LTX no longer reacted with MAb Ltx35, a
leukotoxin- neutralizing monoclonal antibody, after storage at -80o C. The frequent
appearance of multiple protein bands in GST-LTX preparations is also suggestive of
product deterioration. It is possible that the purification process altered the protein’s
conformation in a fashion that would hasten proteolytic degradation. However, fresh
preparations of GST-LTX consistently reacted with MAb Ltx35. It is likely that
degradation occurred at the time of processing or after thawing, since little physical or
enzymatic activity would be expected during storage at -80o C. The difference in the
number of epitopes in these antigens does not appear to be a significant factor in these
observations, since the molar proportion of LTX epitopes was approximately one third in
the GST-LTXFIM antigen compared to GST-LTX. Also, the fusion of GST, a peptide of
similar size to FIM N, to the carboxy- terminus of GST-LTX, did not effectively enhance
the anti- leukotoxin antibody response. Therefore, it is probable that secondary or tertiary
protein structure interactions in GST-LTXFIM provided greater LTX epitope exposure.
These interactions may have been absent in GST- LTX or GST-LTXGST. FIM N is
highly immunogenic; its hydrophobic nature and T-cell epitopes might have aided in
enhanced antigen presentation and antibody response. The general insolubility and
resistance of fimbrial proteins to chemical and proteolytic degradation (15) might also
have predictably contributed to the enhanced immune response.
Vaccines incorporating live M. haemolytica organisms or whole toxin may produce
febrile reactions and result in a lower generalized immune response (7). A stable
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leukotoxin subunit vaccine component would seem to hold great promise for improving
bovine health. The immunogenicity of LTX- FIM N recombinant protein in cattle and
role of FIM N as an immunomodulatory antigen merit further study.
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Figure 1
SDS-PAGE and Western blot of E. coli whole-cell lysates harboring recombinant
plasmids.
A. SDS-PAGE- Whole-cell lysates of E. coli (BL21-Gold) expressing the recombinant
proteins were separated on a 10% polyacrylamide gel and stained with Pierce Gel
Code Blue Stain reagent. Pre-stained molecular weight markers in kDa (Bio-Rad)
(lane 1), Native leukotoxin (lane 2), GST-LTX (lane 3), GST-LTXFIM (lane 4), GSTFIM (lane 5), GST-LTXGST (lane 6). Arrows indicate prominent bands corresponding
to the predicted molecular weight of expected recombinant proteins.
B. Western blot- Proteins were electro-transferred on to a nitrocellulose membrane and
probed with anti- leukotoxin monoclonal antibody, MAb Ltx35.
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Figure 2
SDS-PAGE of recombinant proteins used for immunization.
Recombinant proteins were purified by affinity chromatography. Approximately 15µg of
each protein was electrophoresed on a 10% polyacrylamide gel and stained with Pierce
Gel Code Blue Stain reagent. Pre-stained molecular weight markers in kDa (Bio-Rad)
(lane 1), GST-LTXFIM (lane 2), GST-LTX (lane 3), GST-FIM (lane 4).
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Figure 3
SDS-PAGE and Western blot of recombinant GST- LTX and GST-LTXFIM stored at 80o C for 1 year.
A. SDS-PAGE -Approximately 15µg of each protein was electrophoresed on a 10%
polyacrylamide gel and stained with Pierce Gel Code Blue Stain reagent. Pre-stained
molecular weight markers in kDa (Bio-Rad) (lane 1) GST-LTX (lane 2) GST-LTXFIM
(lane 3)
B. Western blot. The proteins were electro-transferred to nitrocellulose and probed with
anti- leukotoxin antibody MAb Ltx35.
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Figure 4
Antibody response of individual groups of mice immunized with recombinant proteins
Mice were immunized with three successive injections of antigens on days1, 14 and 35
as described in text. (1). GST-LTXFIM in CFA, (2). GST- LTX in CFA, (3). GSTLTXFIM in IFA, (4). GST-LTX in IFA, (5). GST-LTXFIM in PBS, (6). GST-LTX in
PBS, (7). GST- LTXGST in IFA, (8). GST-LTXFIM in IFA (stored), (9). GST-LTX in
IFA (stored), (10). Control (CFA+PBS). The composition of first immunization was as
given above. The second dose of antigen had similar adjuvant composition but CFA was
substituted with IFA, and antigen alone in PBS was used for third dose in each group.
Dark bars represent LTX with
FIM N, while lighter bars represent LTX immunogens without FIM N. The significance
of differences in responses from immunized groups was analyzed by Student’s t-test. A
p-value <0.05 was considered significant. Presence of asterisk indicates the values are
significantly different from control animals. (* = p< 0.001., ** = p< 0.01., *** =
p<0.05).
A. Mean anti- leukotoxin IgG ELISA titers +/- SEM is reported.
B. Leukotoxin neutralization activity is expressed as the percentage of neutralization of
15 units of leukotoxin by a 1:60 dilution of serum measured on two different days.
The mean +/-SEM is reported. The number shown above each bar is the number of
mice that had greater than 50% leukotoxin neutralization activity out of the total
number tested.
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Figure 5
Effect of GST-LTXFIM antigen dose on anti- leukotoxin antibody response in mice.
Mice were inoculated I.P. on days 0, 14, and 35 with GST-LTXFIM. The first two doses
were in IFA and last in PBS. The significance of differences in responses from
immunized groups was analyzed by Student ’s t-test. A p-value <0.05 was considered
significant. Presence of asterisk indicates the values are significantly different from
control animals. (* = p< 0.001., ** = p< 0.01., *** = p<0.05).
A. Mean anti- leukotoxin IgG titers +/- SEM.
B. Leukotoxin neutralization activity is expressed as the percentage of neutralization of
15 units of leukotoxin by a 1:60 dilution of serum. The mean +/- SEM is reported.
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TABLE 1. Descriptions of plasmids used in this study
Plasmid
Description

PCR 2.1

TA Cloning vector (Invitrogen) Ampicillin resistance

pGEX-5X-1

GST gene fusion expression vector (Pharmacia).

PCR2-FIM

fim N gene with regulatory and coding
sequence in EcoRI and HindIII sites of PCR 2.1 (14)

pGEX-FIM

fim N gene coding sequence without the putative signal sequence
in EcoRI and XhoI sites of pGEX-5X-1 (this study) (GSTFIM)A

pGEX-LT FUSION

Leukotoxin A gene nucleotides encoding carboxy-terminal
amino acids 713-939 in EcoRI and XhoI sites of pGEX-4T-1
(16)

pGEX-LTBE

Leukotoxin A gene nucleotides encoding carboxy-terminal
aminoacids 719-939 from pGEX LT FUSION in BamH I and
EcoRI sites of pGEX- 5X-1 (this study) (GST-LTX)A

pGEX-LTFIM

Leukotoxin A gene fragment in BamHI and EcoRI sites and fim
N gene in EcoRI and XhoI sites of pGEX-5x-1.(this study) (GSTLTXFIM )A

pGEX-LTGST

GST gene fragment cloned downstream to LTX in XhoI site of
pGEX-LT FUSION. (This study) (GST-LTXGST)A

pPROEXTM-HT-FIM fim N gene without the signal sequence in
pPROEXT M HT (Gibco/BRL) (HTFIM)A (14)

Letters in the parenthesis with superscript A indicate the name of the protein expressed
by the plasmids.
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PART 5
General Summary
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Summary
The first part of this research work was focused on identifying constitutive
promoters suitable for heterologous antigen expression in B. bronchiseptica. This
investigation resulted in isolation and characterization of a promoter region related to
heat shock gene family. The promoter was active in vitro and was able to induce highlevel expression of GFP. The taco promoter, which is an E. coli derived promoter, was
also active inB. bronchiseptica. Low- level activity of Fim N promoter was detected in
Bvg+ strains of B. bronchiseptica indicating that this promoter was Bvg-regulated. The
low level activity of this promoter was enhanced by growth in a minimal salt media and
may be further enhanced by manipulating the C-stretch region of the promoter. The
promoter we identified belonged to the family of heat shock genes. These genes are
usually induced under stress conditions. However this study did not identify any
induction condition for this promoter region.
The plasmid used to express heterologous antigen in B. bronchiseptica was originally
isolated from B. bronchiseptica. However, the reconstructed plasmid was not stable in
vivo or in vitro under non-selective condition. The foreign DNA engineered into the
plasmid and heterologous antigen expression may be the factors contributing to plasmid
instability. Identification of moderately active promoters, construction of more stable
plasmids, and chromosomal integration of the foreign gene can be pursued
In the second part of the study, we expressed a non-toxic protective P. multocida
toxin fragment (PMTCE) in B. bronchiseptica under the control of the promoter we
identified. However, the level of expression of this protein was very low. Intranasal
inoculation with B. bronchiseptica expressing PMTCE did not induce a PMT-specific
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antibody response. Mucosal and systemic antibody response was gene rated against B.
bronchiseptica. However, four intranasal inoculations at 14 day intervals with B.
bronchiseptica expressing GFP induced a mucosal and systemic immune response
against GFP. Factors like differences in the antigenicity, low level expression and
plasmid instability might have contributed to the difference in immune response to these
two heterologous antigens expressed by B. bronchiseptica. Improvement in plasmid
stability and antigen expression is required to improve the system.
The third part of this study evaluated the immune response to a chimeric protein
created by fusing the FIM N protein of B. bronchiseptica and an unstable protective
fragment of Mannheimia haemolytica leukotoxin. Immunization of mice with this
chimeric protein elicited stronger anti- leukotoxin antibodies than similar immunization
with protein, which lacks the FIM N. Also, the molecular chimerization improved the
stability of the leukotoxin fragment. This protein may be an efficient vaccine candidate to
prevent M. haemolytica-induced shipping fever in feedlot cattle. Adhesins are excellent
targets for vaccine development and they have been explored as potential vehicles for
delivery of heterologous antigens. FIM N protein may be an effective carrier for
heterologous antigen delivery in B. bronchiseptica. However, the immunomodulatory
property of FIM N needs further investigation.
Atrophic rhinitis is a disease of significant economic importance to US agriculture.
The involvement of B. bronchiseptica and P. multocida in this disease condition is well
documented. This study provides basis for the development of an improved, single
component vaccine against atrophic rhinitis. However, optimization of antigen expression
to induce an effective immune response is required. Further genetic modification to
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inactivate the important virulence factors of B. bronchiseptica has to be pursued. Since B.
bronchiseptica can colonize the respiratory tract of wide variety of host species, potential
for applying this model to other species and diseases is great. Utilizing the benign
colonization of B. bronchiseptica to deliver a protective antigen will be a potent way to
induce a mucosal immune response at the respiratory tract mucosa.
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